<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cutaneous manifestations of tuberculosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cutaneous manifestations of tuberculosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cutaneous manifestations of tuberculosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Evangeline B Handog, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria Juliet E Macarayo, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ted Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H494561"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tuberculosis (TB) is a mycobacterial infection that most frequently occurs due to infection with <em>Mycobacterium tuberculosis</em>, an acid-fast bacillus. Although there has been progress in the delivery of TB care and a decline in TB-related deaths globally, TB still remains a major public health concern [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/8018.html" rel="external">"Epidemiology of tuberculosis", section on 'Global burden'</a>.)</p><p>Cutaneous involvement is a relatively uncommon manifestation of TB. The clinical findings vary and include papules, verrucous plaques, suppurative nodules, chronic ulcers, and other lesions. The pathway of bacterial entry into the skin, the host's immune status, and the presence or absence of prior host sensitization to <em>M. tuberculosis </em>influence the morphologic presentation of cutaneous TB.</p><p>The cutaneous disorders associated with TB will be reviewed here. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary inoculation TB  (<a class="graphic graphic_picture graphicRef129875" href="/z/d/graphic/129875.html" rel="external">picture 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TB verrucosa cutis  (<a class="graphic graphic_picture graphicRef129880 graphicRef81731" href="/z/d/graphic/129880.html" rel="external">picture 2A-B</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scrofuloderma  (<a class="graphic graphic_picture graphicRef72008 graphicRef129881" href="/z/d/graphic/72008.html" rel="external">picture 3A-B</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TB cutis orificialis  (<a class="graphic graphic_picture graphicRef51950" href="/z/d/graphic/51950.html" rel="external">picture 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lupus vulgaris  (<a class="graphic graphic_picture graphicRef64828" href="/z/d/graphic/64828.html" rel="external">picture 5</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metastatic tuberculous abscesses  (<a class="graphic graphic_picture graphicRef65877" href="/z/d/graphic/65877.html" rel="external">picture 6</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute miliary TB</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculids (papulonecrotic tuberculid  (<a class="graphic graphic_picture graphicRef74606 graphicRef55062" href="/z/d/graphic/74606.html" rel="external">picture 7A-B</a>), lichen scrofulosorum  (<a class="graphic graphic_picture graphicRef63717" href="/z/d/graphic/63717.html" rel="external">picture 8</a>), erythema induratum of Bazin [EIB]  (<a class="graphic graphic_picture graphicRef76526 graphicRef53596 graphicRef64335" href="/z/d/graphic/76526.html" rel="external">picture 9A-C</a>))</p><p></p><p>General principles of TB are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8007.html" rel="external">"Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8018.html" rel="external">"Epidemiology of tuberculosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8023.html" rel="external">"Tuberculosis: Natural history, microbiology, and pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7026.html" rel="external">"Pulmonary tuberculosis: Clinical manifestations and complications"</a>.)</p><p></p><p class="headingAnchor" id="H22503288"><span class="h1">HISTORY</span><span class="headingEndMark"> — </span>Cutaneous TB was first documented in 1826, when Laennec reported his own "prosector's wart," a lesion that likely represented TB verrucosa cutis, a variant of TB that results from direct entry of the organism into the skin [<a href="#rid2">2</a>]. However, the causative organism of TB was unknown until the discovery of <em>M. tuberculosis</em> in 1882 [<a href="#rid3">3</a>]. Subsequently, the bacillus was detected in cutaneous lesions [<a href="#rid4">4</a>]. (See <a class="local">'True cutaneous tuberculosis'</a> below.)</p><p class="headingAnchor" id="H2970456368"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Cutaneous TB is a relatively uncommon manifestation of TB. According to World Health Organization (WHO) 2019 data, extrapulmonary TB constituted 15 percent of the seven million incident cases in 2018 [<a href="#rid1">1</a>]. Cutaneous lesions account for less than 2 percent of all extrapulmonary manifestations [<a href="#rid5">5-7</a>].</p><p>Similar to other forms of TB, a resurgence of cutaneous TB has been noted in parts of the world where HIV infection and multidrug-resistant TB are prevalent [<a href="#rid8">8-10</a>]. (See  <a class="medical medical_review" href="/z/d/html/8018.html" rel="external">"Epidemiology of tuberculosis", section on 'Global burden'</a>.)</p><p class="headingAnchor" id="H605174"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>TB is defined as a disorder caused by mycobacteria in the <em>M. tuberculosis</em> complex, which includes <em>M. tuberculosis</em>, <em>Mycobacterium bovis</em>, <em>Mycobacterium africanum</em>, <em>Mycobacterium microti</em>, <em>Mycobacterium canettii</em>, <em>Mycobacterium caprae</em>, and <em>Mycobacterium</em> <em>pinnipedii</em> [<a href="#rid11">11</a>]. <em>M. tuberculosis</em>, a slow-growing, acid-fast bacillus, is the predominant causative organism of cutaneous TB. (See  <a class="medical medical_review" href="/z/d/html/8023.html" rel="external">"Tuberculosis: Natural history, microbiology, and pathogenesis", section on 'Microbiology'</a>.)</p><p><em>M. bovis</em> and the Bacille Calmette-Guérin (BCG) vaccine (a vaccine composed of attenuated <em>M. bovis</em>) have also been associated with the development of cutaneous lesions [<a href="#rid12">12-14</a>]. (See  <a class="medical medical_review" href="/z/d/html/8006.html" rel="external">"Mycobacterium bovis"</a> and <a class="local">'Bacille Calmette-Guérin vaccination reactions'</a> below.)</p><p class="headingAnchor" id="H494648"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Classification systems for cutaneous TB vary. Commonly, cutaneous TB is divided into two major groups: <strong>true cutaneous TB</strong> and <strong>tuberculids</strong> [<a href="#rid10">10</a>]. (See <a class="local">'True cutaneous tuberculosis'</a> below and <a class="local">'Tuberculids'</a> below.)</p><p>True cutaneous TB includes conditions in which cutaneous lesions are a direct manifestation of infection at the site of the skin lesions. In true cutaneous TB, mycobacteria can be identified in the sites of skin involvement using tests such as smears, in situ hybridization of pathology specimens, or cultures [<a href="#rid10">10</a>]. Detection may be more difficult in some forms of true cutaneous TB. (See <a class="local">'Bacterial load'</a> below.)</p><p>In contrast, tuberculids are considered to result from a hypersensitivity reaction to mycobacterial antigens. Mycobacteria typically are not detectable via smears, histopathologic techniques, or cultures from tuberculid lesions. (See <a class="local">'Tuberculids'</a> below.)</p><p class="headingAnchor" id="H2597431812"><span class="h2">True cutaneous tuberculosis</span><span class="headingEndMark"> — </span>The characteristic most often used to subdivide true cutaneous TB is the mode of infection. The quantity of organisms typically present in the skin (bacterial load) is another method of classification. (See <a class="local">'Mode of infection'</a> below and <a class="local">'Bacterial load'</a> below.)</p><p class="headingAnchor" id="H709682934"><span class="h3">Mode of infection</span><span class="headingEndMark"> — </span>Most cases of true cutaneous TB arise from contiguous spread or hematogenous dissemination to the skin from an endogenous focus of infection. Direct entry of <em>M. tuberculosis</em> into the skin (ie, inoculation from an exogenous source) occasionally results in localized infection [<a href="#rid15">15,16</a>]. (See <a class="local">'True cutaneous tuberculosis'</a> below.)</p><p>Classification according to mode of infection:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contiguous spread or autoinoculation </strong>(see <a class="local">'Contiguous spread'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Scrofuloderma</p><p class="bulletIndent2"><span class="glyph">•</span>TB cutis orificialis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematogenous spread to the skin</strong> (see <a class="local">'Hematogenous spread'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lupus vulgaris </p><p class="bulletIndent2"><span class="glyph">•</span>Acute miliary TB</p><p class="bulletIndent2"><span class="glyph">•</span>Metastatic tuberculous abscess </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inoculation from an exogenous source </strong>(see <a class="local">'Exogenous inoculation'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary inoculation TB/TB chancre</p><p class="bulletIndent2"><span class="glyph">•</span>TB verrucosa cutis</p><p></p><p class="headingAnchor" id="H711841554"><span class="h3">Bacterial load</span><span class="headingEndMark"> — </span>True cutaneous TB may also be classified according to the bacterial load in the skin [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multibacillary forms</strong> (bacilli easily detectable in tissue or exudate):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary inoculation TB/TB chancre </p><p class="bulletIndent2"><span class="glyph">•</span>Scrofuloderma</p><p class="bulletIndent2"><span class="glyph">•</span>TB cutis orificialis</p><p class="bulletIndent2"><span class="glyph">•</span>Acute miliary TB</p><p class="bulletIndent2"><span class="glyph">•</span>Metastatic tuberculous abscess</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paucibacillary forms</strong> (bacilli hard to detect in tissue or exudate):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TB verrucosa cutis</p><p class="bulletIndent2"><span class="glyph">•</span>Lupus vulgaris</p><p></p><p class="headingAnchor" id="H810282093"><span class="h2">Tuberculids</span><span class="headingEndMark"> — </span>The <strong>tuberculids</strong> are TB-associated cutaneous disorders that represent hypersensitivity reactions to mycobacterial antigens, rather than manifestations of local skin infection. (See <a class="local">'Tuberculids'</a> below.)</p><p>The tuberculids include:</p><p class="bulletIndent1"><span class="glyph">●</span>Papulonecrotic tuberculid</p><p class="bulletIndent1"><span class="glyph">●</span>Lichen scrofulosorum</p><p class="bulletIndent1"><span class="glyph">●</span>Erythema induratum of Bazin (EIB)</p><p></p><p class="headingAnchor" id="H22503325"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The major risk factors for the development of TB are increased exposure to sources of infection and immunologic susceptibility of the host to infection. (See  <a class="medical medical_review" href="/z/d/html/8018.html" rel="external">"Epidemiology of tuberculosis", section on 'Risk factors'</a>.)</p><p>Host factors that appear to influence risk for specific cutaneous manifestations of TB include age, sex, and immune status [<a href="#rid18">18-21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age and sex</strong> – Primary inoculation TB, scrofuloderma, and lichen scrofulosorum commonly affect children, and lupus vulgaris affects adults. Erythema induratum of Bazin (EIB) occurs more frequently in females than in males. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune status</strong> – Poor immunity against <em>M. tuberculosis</em> is a risk factor for TB cutis orificialis, metastatic tuberculous abscess, and acute miliary TB [<a href="#rid3">3,15</a>]. Higher levels of immunity against <em>M. tuberculosis</em> are linked with TB verrucosa cutis, lupus vulgaris, and tuberculids [<a href="#rid15">15</a>]. (See <a class="local">'True cutaneous tuberculosis'</a> below.)</p><p></p><p class="headingAnchor" id="H22503346"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>The characteristic histopathologic finding in true cutaneous TB is the <strong>tuberculoid granuloma</strong>, an accumulation of epithelioid histiocytes and Langhans-type giant cells that demonstrates a variable degree of central caseation necrosis and a peripheral rim composed of numerous lymphocytes  (<a class="graphic graphic_picture graphicRef129884 graphicRef74597" href="/z/d/graphic/129884.html" rel="external">picture 10A-B</a>) [<a href="#rid22">22,23</a>].</p><p>Although tuberculoid granulomas are a common finding, their detection does not confirm the presence of TB, and their absence does not exclude the diagnosis. Leprosy, tertiary syphilis, granulomatous rosacea, leishmaniasis, deep fungal infections, and other disorders may also present with tuberculoid granulomas [<a href="#rid23">23-25</a>].</p><p>Tuberculoid granulomas should be distinguished from the classic granulomas of sarcoidosis. Compared with tuberculoid granulomas, sarcoidal granulomas tend to be more circumscribed, exhibit fewer peripheral inflammatory cells ("naked granulomas"), and are not likely to have central caseation necrosis  (<a class="graphic graphic_picture graphicRef80383 graphicRef54204" href="/z/d/graphic/80383.html" rel="external">picture 11A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">"Cutaneous manifestations of sarcoidosis", section on 'Histopathology'</a>.)</p><p class="headingAnchor" id="H494576"><span class="h1">DIAGNOSTIC APPROACH</span><span class="headingEndMark"> — </span>Suspicion for cutaneous TB can arise from the recognition of suggestive clinical lesions during a physical examination or the detection of features supportive of cutaneous TB on a skin biopsy. Multiple tests are used to evaluate patients for cutaneous manifestations of TB. (See <a class="local">'General approach'</a> below and <a class="local">'Specific tests'</a> below and <a class="local">'Challenging cases'</a> below.)</p><p class="headingAnchor" id="H3244896884"><span class="h2">General approach</span><span class="headingEndMark"> — </span>The diagnosis of a cutaneous TB is typically made based upon the detection of consistent clinical, pathologic, and laboratory findings. Methods of detecting the causative mycobacteria include mycobacterial culture (the gold standard for diagnosis of true cutaneous TB), stained smears, and lesional biopsies. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults", section on 'Microbiologic testing'</a>.)</p><p>Tests that evaluate for immunologic evidence of infection, such as tuberculin skin testing and interferon-gamma release assays, can be helpful for supporting a diagnosis, particularly when the results of pathologic and microbiologic assessments are negative or inconclusive. Additionally, nucleic acid amplification (NAA) tests to detect mycobacterial deoxyribonucleic acid (DNA) may play a role in diagnosis.</p><p>For patients who present with clinical features that raise suspicion for cutaneous TB, our typical initial approach includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Lesional skin biopsy for histopathologic examination</p><p class="bulletIndent1"><span class="glyph">●</span>Acid-fast bacilli (AFB) smear from exudate or biopsy tissue</p><p class="bulletIndent1"><span class="glyph">●</span>Mycobacterial culture from exudate or biopsy tissue</p><p class="bulletIndent1"><span class="glyph">●</span>Testing for immunologic evidence of TB infection (<a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> or interferon-gamma release assay)</p><p></p><p>The expected results of these tests vary based upon the specific diagnosis. Culture, smears, and histopathology often fail to detect <em>M. tuberculosis</em> in paucibacillary variants of cutaneous TB due to the relatively low number of organisms in lesional tissue. Similarly, cultures and smears are not typically useful for the diagnosis of tuberculids, in which mycobacteria generally are not detected in skin lesions. (See <a class="local">'True cutaneous tuberculosis'</a> below and <a class="local">'Tuberculids'</a> below.)</p><p>NAA tests are primarily used as an adjunct to clinicopathologic and microbiologic evaluation for cutaneous TB [<a href="#rid24">24</a>]. Although NAA testing is an established diagnostic test for pulmonary TB, the role NAA testing should play in the diagnosis of cutaneous TB is being explored, particularly in cases in which detection of <em>M. tuberculosis</em> through other means is difficult [<a href="#rid26">26-29</a>]. (See <a class="local">'Specific tests'</a> below.)</p><p>In scenarios in which strong clinical suspicion for cutaneous TB remains despite an inability to confirm the diagnosis with histopathology or laboratory tests, a response to an empirical trial of anti-TB therapy can support the diagnosis. (See <a class="local">'Challenging cases'</a> below.)</p><p class="headingAnchor" id="H652643385"><span class="h2">Specific tests</span><span class="headingEndMark"> — </span>Tests utilized in the diagnosis of cutaneous manifestations of TB are briefly reviewed below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Detection of mycobacteria or tissue findings consistent with cutaneous manifestations of TB</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mycobacterial culture </strong>– Mycobacterial culture remains the gold standard for determining the presence of active TB infection, providing the means to distinguish <em>M. tuberculosis </em>from nontuberculous mycobacteria and allowing the determination of antibiotic sensitivity [<a href="#rid5">5,13,15,30-32</a>]. A tissue biopsy of the skin lesion(s) is the recommended specimen for culture; discharge from draining lesions may be used as well [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent2">Concerns about mycobacterial culture, especially with the paucibacillary forms, are the potential for low mycobacterial yields and the slow growth rate <em>of M. tuberculosis</em>. Results may be delayed for one to several weeks, depending upon the culture method [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults", section on 'Mycobacterial culture'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acid-fast bacilli (AFB) smear </strong>– The examination for AFB on a stained smear is a more rapid diagnostic technique than culture. The diagnostic yield of stained smears is highest for moist or exudative lesions that have a high bacterial load, such as primary inoculation TB, scrofuloderma, TB cutis orificialis, or metastatic tuberculous abscess. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults", section on 'Sputum AFB smear'</a>.)</p><p></p><p class="bulletIndent2">The specimen for an AFB smear is best derived from a tissue biopsy taken from the edge of an actual skin lesion. For cutaneous TB lesions from which exudates are easily obtained, exudate can also serve as a specimen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Skin biopsy for histopathologic examination </strong>–<strong> </strong>The accessibility of skin lesions makes the obtainment of a tissue biopsy a relatively simple procedure. Biopsies of cutaneous manifestations of TB can reveal tuberculoid granulomas, AFB, or other characteristic histopathologic features of specific variants. (See <a class="local">'Histopathology'</a> above and <a class="local">'True cutaneous tuberculosis'</a> below and <a class="local">'Tuberculids'</a> below.)</p><p></p><p class="bulletIndent2">The preferred biopsy technique is an incisional biopsy at the edge of the representative lesion. A 3 to 5 mm punch biopsy tool may also be used to obtain a specimen [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Detection of immunologic evidence of </strong><strong><em>M. tuberculosis </em></strong><strong>infection</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">Tuberculin skin test</a> – The tuberculin skin test identifies individuals sensitized to <em>M. tuberculosis </em>[<a href="#rid31">31,32,35,36</a>]. The immunologic basis for the tuberculin skin test is a delayed hypersensitivity reaction involving T cells. (See  <a class="medical medical_review" href="/z/d/html/8005.html" rel="external">"Use of the tuberculin skin test for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8020.html" rel="external">"Tuberculosis infection (latent tuberculosis) in children", section on 'Tuberculin skin test'</a>.)</p><p></p><p class="bulletIndent2">The Mantoux technique, the recommended method for performing tuberculin skin testing, involves the intradermal injection of 0.1 mL tuberculin antigen (purified protein derivative [PPD]) into the inner surface of the forearm, followed by re-examination of the injection site for induration (not erythema) 48 to 72 hours later  (<a class="graphic graphic_table graphicRef67357" href="/z/d/graphic/67357.html" rel="external">table 1</a>). It has a specificity of 63 percent and a sensitivity between 33 and 96 percent for cutaneous TB that becomes higher in unvaccinated populations [<a href="#rid12">12,37</a>]. Reactivity to the tuberculin protein may be impaired in young infants, older adults, and patients with deficient cellular immunity  (<a class="graphic graphic_table graphicRef58908" href="/z/d/graphic/58908.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Interferon-gamma release assay </strong>–<strong> </strong>Interferon-gamma release assays are serologic tests that assess for latent TB infection via the measurement of interferon-gamma production from peripheral blood mononuclear cells after exposure to antigens from<em> M. tuberculosis</em> [<a href="#rid24">24,35</a>]. A study evaluating an interferon-gamma release assay (T-SPOT.TB) in patients with suspected cutaneous TB found a sensitivity of 92 percent and a specificity of 76 percent [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/15352.html" rel="external">"Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a>.)</p><p></p><p class="bulletIndent2">Unlike the <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a>, the Bacille Calmette-Guérin (BCG) vaccination does not influence the results of this test. However, prior infections with select environmental mycobacteria, such as <em>Mycobacterium marinum</em>, <em>Mycobacterium kansasii</em>, and <em>Mycobacterium szulgai</em>, may result in a false-positive interferon-gamma release assay [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/15352.html" rel="external">"Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Detection of </strong><strong><em>M. tuberculosis</em></strong><strong> DNA</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NAA tests</strong> – NAA tests for <em>M. tuberculosis</em> detect <em>M. tuberculosis</em> DNA in tissue specimens. These tests provide rapid results (within two hours), can differentiate between <em>M. tuberculosis</em> and other species of mycobacteria, and may identify gene mutations associated with drug resistance (including <em>rpoB</em> gene for rifampicin resistance) [<a href="#rid32">32,40</a>]. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults", section on 'NAA (probe-based) testing'</a>.)</p><p></p><p class="bulletIndent2">In the evaluation of cutaneous TB, NAA tests are primarily used as an adjunct to clinicopathologic and microbiologic evaluation [<a href="#rid24">24</a>]. The potential advantage of NAA testing is rapid detection <em>of M. tuberculosis</em>, especially when AFB staining and culture results are negative or when fresh tissue or exudate has not been collected for culture [<a href="#rid41">41</a>]. </p><p></p><p class="bulletIndent2">Sensitivity and specificity of NAA tests vary from 25 to 100 percent and 74 to 100 percent, respectively [<a href="#rid29">29</a>]. NAA tests may most likely be positive in the multibacillary forms of cutaneous TB [<a href="#rid42">42-45</a>]. Although NAA tests may be positive in paucibacillary disease when both cultures and histopathologic stains for the organism are negative, the results of testing are inconsistent [<a href="#rid43">43,46-50</a>]. In addition, the availability of NAA testing in resource-limited countries is another constraint [<a href="#rid43">43,47,51</a>].</p><p></p><p class="headingAnchor" id="H3410794266"><span class="h2">Challenging cases</span><span class="headingEndMark"> — </span>In difficult cases, a therapeutic trial of anti-TB medications may be used to confirm the diagnosis of cutaneous TB.<strong> </strong>For true cutaneous TB, a response to multidrug therapy is usually evident within six weeks [<a href="#rid51">51-53</a>]. Expectations for tuberculid responses to anti-TB therapy are reviewed below. (See <a class="local">'Tuberculids'</a> below.)</p><p>The diagnosis should be re-evaluated in patients who fail to improve within the expected period. Of note, improvement may be less easily detected in patients with minimal clinical activity prior to treatment [<a href="#rid52">52</a>]. (See <a class="local">'Treatment overview'</a> below.)</p><p class="headingAnchor" id="H22503353"><span class="h1">TRUE CUTANEOUS TUBERCULOSIS</span><span class="headingEndMark"> — </span>The characteristics of the subtypes of true cutaneous TB, grouped according to mode of infection (exogenous inoculation, contiguous spread, or hematogenous spread), are reviewed below. </p><p class="headingAnchor" id="H2020187"><span class="h2">Exogenous inoculation</span><span class="headingEndMark"> — </span>Primary inoculation TB and TB verrucosa cutis are acquired through the inoculation of the organism into the skin. Primary inoculation TB occurs in individuals who have not previously been sensitized to <em>M. tuberculosis</em>, whereas TB verrucosa cutis develops in individuals with prior exposure to the bacterium. TB verrucosa cutis is much more common than the primary inoculation variant [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H22503362"><span class="h3">Primary inoculation tuberculosis</span><span class="headingEndMark"> — </span>Primary inoculation TB is<strong> </strong>a rare multibacillary form of cutaneous TB that results from the direct entry of the organism into the skin or mucosa of a nonsensitized individual:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative terms</strong> – Tuberculous chancre, primary tuberculous complex.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Primary inoculation TB primarily occurs in children in endemic areas [<a href="#rid3">3</a>] but has been reported in adults as well [<a href="#rid54">54,55</a>]. Minor trauma resulting in a compromised skin barrier usually precedes the infection. Surgical procedures performed with unsterilized equipment, tattoos, piercings, and acupuncture sites may also lead to lesion development [<a href="#rid39">39,54,56,57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>–<strong> </strong>Primary inoculation TB becomes clinically evident within one month after inoculation. The classic lesion begins as a nondescript, red-brown papule or nodule that evolves into a painless, shallow and undermined ulcer with a granulomatous base. Lesions are usually 1 cm or less in diameter but occasionally exceed 5 cm [<a href="#rid3">3</a>]. Significant crusting may occur.</p><p></p><p class="bulletIndent1">Primary inoculation TB is generally located in the upper limbs, lower limbs, or the buttocks [<a href="#rid39">39</a>]. The hands may be the most frequent location [<a href="#rid13">13,58</a>]. Sporotrichoid presentations (ie, linear distribution of nodules along lymphatic vessels) have been reported  (<a class="graphic graphic_picture graphicRef129875" href="/z/d/graphic/129875.html" rel="external">picture 1</a>) [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1">Slowly progressive and painless regional lymphadenopathy frequently becomes apparent three to eight weeks after the appearance of the skin lesion. Occasionally, lymph node involvement results in perforation of the skin and the development of draining sinuses [<a href="#rid3">3,42</a>]. The combination of the cutaneous findings and lymphadenopathy in primary inoculation TB are analogous to the Ghon complex of pulmonary TB infection [<a href="#rid17">17,58</a>]. (See  <a class="medical medical_review" href="/z/d/html/7026.html" rel="external">"Pulmonary tuberculosis: Clinical manifestations and complications", section on 'Natural history'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– A diagnosis of primary inoculation TB can often be made through a smear or skin biopsy taken from an early lesion. Early primary inoculation TB is multibacillary, and acid-fast bacilli (AFB) are usually easily detected [<a href="#rid23">23,60,61</a>]. A positive culture confirms the diagnosis.</p><p></p><p class="bulletIndent1">Skin biopsies obtained early in the disease course reveal necrosis, neutrophilic infiltrates, and numerous AFB [<a href="#rid3">3</a>]. In contrast, lesions that have been present for several weeks or longer demonstrate tuberculoid granulomas with or without caseation necrosis, and few or no bacilli [<a href="#rid60">60,62,63</a>]. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1">The <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> is typically negative at the time of disease onset but later becomes positive [<a href="#rid55">55,64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– The differential diagnosis of primary inoculation TB includes other disorders that may present with inflammatory nodules or ulcers. Examples include abscesses, foreign body granulomas, sarcoidosis, and other nontuberculous mycobacterial infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease course </strong>–<strong> </strong>Left untreated, primary inoculation TB may spontaneously regress or may persist for up to one year [<a href="#rid3">3,39</a>]. A scar typically remains after resolution, with calcification of the regional lymph nodes [<a href="#rid39">39,58</a>]. (See <a class="local">'Treatment overview'</a> below.)</p><p></p><p class="bulletIndent1">Hematogenous spread of the bacillus leading to TB of other organs or acute miliary disease is a potential complication [<a href="#rid23">23</a>]. Erythema nodosum occurs in approximately 10 percent of cases [<a href="#rid3">3</a>]. Occasionally, lupus vulgaris, scrofuloderma, or TB verrucosa cutis develops at the site of a lesion [<a href="#rid3">3,58</a>]. (See  <a class="medical medical_review" href="/z/d/html/8024.html" rel="external">"Clinical manifestations, diagnosis, and treatment of miliary tuberculosis"</a> and  <a class="medical medical_review" href="/z/d/html/5612.html" rel="external">"Erythema nodosum"</a>.)</p><p></p><p class="headingAnchor" id="H22503369"><span class="h3">Tuberculosis verrucosa cutis</span><span class="headingEndMark"> — </span>TB verrucosa cutis is<strong> </strong>a paucibacillary form of cutaneous TB that occurs after direct inoculation of the mycobacteria into the skin of a previously sensitized host with moderate to high immunity against the bacillus [<a href="#rid15">15,23,31,42</a>]. Inoculation typically occurs from an exogenous source; rarely, inoculation may occur from the patient's own sputum [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative terms </strong>– Prosector's wart, anatomic TB, verruca necrogenica, warty TB.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Children who play in contaminated areas and adults with occupational exposure to mycobacteria (eg, pathologists, laboratory technicians, undertakers, butchers, and farmers) are at greatest risk for this infection [<a href="#rid3">3,65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>–<strong> </strong>In adults, TB verrucosa cutis most frequently develops on the acral extremities; the fingers and dorsum of the hands are commonly affected [<a href="#rid3">3,24,31,65-67</a>]. The ankles or buttocks are frequent sites for lesion occurrence in children [<a href="#rid31">31</a>]. Rare lip involvement has been reported [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1">The skin lesions are usually solitary and manifest as painless, violaceous or brown-red, indurated, warty plaques that range from 1 to 5 cm in diameter  (<a class="graphic graphic_picture graphicRef129880 graphicRef81731" href="/z/d/graphic/129880.html" rel="external">picture 2A-B</a>). TB verrucosa cutis grows via peripheral extension; central clearing and atrophy may or may not be present [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent1">Although ulceration is uncommon, fissures that exude purulent drainage or keratinous material may occur [<a href="#rid3">3,12</a>]. Other potential clinical findings include regional adenopathy in patients with secondary bacterial infection and lymphostasis and elephantiasis of affected extremities in patients with extensive and chronic involvement [<a href="#rid12">12,66</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>Correlation of the physical findings with a skin biopsy plus other evidence of TB infection, such as a positive <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> or interferon-gamma release assay, is the primary method for diagnosing TB verrucosa cutis [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1">The histopathologic findings of TB verrucosa cutis include  (<a class="graphic graphic_picture graphicRef59116" href="/z/d/graphic/59116.html" rel="external">picture 12</a>) [<a href="#rid3">3,23,62,70</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pseudoepitheliomatous hyperplasia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Marked hyperkeratosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Microabscesses in the superficial dermis or the pseudoepitheliomatous rete pegs</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Frequent presence of an inflammatory infiltrate composed of epithelioid cells and giant cells in the upper and middle dermis</p><p></p><p class="bulletIndent1">Frank tuberculoid granulomas may or may not be evident [<a href="#rid3">3,23,62,70</a>].</p><p></p><p class="bulletIndent1">The <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> is typically strongly positive, indicative of the high level of immunity against the bacterium [<a href="#rid31">31,61</a>]. Although a few AFB can be detected on careful histopathologic examination in some cases, cultures taken from lesions of TB verrucosa cutis are often negative [<a href="#rid31">31,42</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– The differential diagnosis of TB verrucosa cutis includes other diseases that may present with hyperkeratotic or verrucous plaques, including atypical mycobacterioses, blastomycosis, Majocchi's granuloma, chromoblastomycosis, tertiary syphilis, verrucous epidermal nevus, hypertrophic lichen planus, hyperkeratotic lupus vulgaris, halogenoderma, benign keratoses, prurigo nodularis, and verruca vulgaris [<a href="#rid23">23,31,61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease course </strong>–<strong> </strong>Skin lesions may persist for years if left untreated, although spontaneous resolution can also occur [<a href="#rid15">15,23,42,61</a>]. Patients typically improve with anti-TB therapy [<a href="#rid42">42</a>]. (See <a class="local">'Treatment overview'</a> below.)</p><p></p><p class="headingAnchor" id="H2020211"><span class="h2">Contiguous spread</span><span class="headingEndMark"> — </span>TB infection can be transmitted to the skin from adjacent structures. Scrofuloderma, TB cutis orificialis, and lupus vulgaris can occur as a result of this process. </p><p class="headingAnchor" id="H4098339077"><span class="h3">Scrofuloderma</span><span class="headingEndMark"> — </span>Scrofuloderma<strong> </strong>is a multibacillary form of cutaneous TB that occurred much more frequently prior to the advent of effective therapies for TB. This disorder results from the direct extension of the infection from a deep structure (eg, lymph node, bone, joint, or epididymis) into the overlying skin [<a href="#rid18">18,42,56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative term</strong> – TB colliquativa cutis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Scrofuloderma may occur at any age but most commonly develops in children, adolescents, and older adult individuals [<a href="#rid23">23,42,61,66</a>]. </p><p></p><p class="bulletIndent1">In addition to <em>M. tuberculosis</em> infection, <em>M. bovis</em> infection related to the consumption of contaminated milk may lead to scrofuloderma [<a href="#rid71">71</a>]. The occurrence of scrofuloderma following Bacille Calmette-Guérin (BCG) vaccination has also been reported [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/8006.html" rel="external">"Mycobacterium bovis"</a> and  <a class="medical medical_review" href="/z/d/html/8022.html" rel="external">"Prevention of tuberculosis: BCG immunization and nutritional supplementation"</a>.)</p><p></p><p class="bulletIndent1">Scrofuloderma has also been reported to occur with other forms of cutaneous TB, such as TB verrucosa cutis [<a href="#rid68">68,73,74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Early lesions of scrofuloderma are firm, painless, subcutaneous, red-brown nodules that overly foci of tuberculous infection  (<a class="graphic graphic_picture graphicRef129881" href="/z/d/graphic/129881.html" rel="external">picture 3B</a>). The neck, axillae, and groin are often involved, with the cervical lymph nodes as the most common source of infection [<a href="#rid3">3,66</a>].</p><p></p><p class="bulletIndent1">The suppurative nodules gradually enlarge and eventually form ulcers and sinus tracts that drain watery, purulent, or caseous material  (<a class="graphic graphic_picture graphicRef72008" href="/z/d/graphic/72008.html" rel="external">picture 3A</a>) [<a href="#rid12">12,42</a>]. Lesions may be single or multiple. A linear arrangement can occur if the infection overlies multiple lymph nodes within a region [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>The diagnosis of scrofuloderma is based upon the identification of the causative organism by culture, smear, or skin biopsy [<a href="#rid12">12</a>]. Skin biopsy reveals tuberculoid granulomas surrounding areas of wedge-shaped necrosis [<a href="#rid42">42,70</a>].</p><p></p><p class="bulletIndent1">Tuberculin skin testing is typically positive, exhibiting a pronounced skin reaction [<a href="#rid23">23,60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>–<strong> </strong>The differential diagnosis includes other causes of suppurative nodules, such as atypical mycobacterioses, sporotrichosis, actinomycosis, nocardiosis, paracoccidioidomycosis, coccidioidomycosis, lymphogranuloma venereum, syphilitic gumma, severe forms of acne conglobata, and hidradenitis suppurativa [<a href="#rid23">23,31,58,61</a>]. In the neck, scrofuloderma may mimic a dental sinus. Detection of <em>M. tuberculosis</em> distinguishes scrofuloderma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease course </strong>–<strong> </strong>Spontaneous healing may occur, but it may be years before lesions are completely replaced by scar tissue [<a href="#rid12">12</a>]. Scars may be depressed, retractable, adherent, hypertrophic, or keloidal [<a href="#rid42">42,60,61,66</a>]. The characteristic scars can lead to the recognition of patients with a prior history of scrofuloderma.</p><p></p><p class="bulletIndent1">Coexistence with an active pulmonary process is relatively common [<a href="#rid61">61,66</a>]. In addition, lupus vulgaris may develop within or near sites of scrofuloderma [<a href="#rid23">23</a>]. (See <a class="local">'Lupus vulgaris'</a> below.)</p><p></p><p class="headingAnchor" id="H22503383"><span class="h3">Tuberculosis cutis orificialis</span><span class="headingEndMark"> — </span>TB cutis orificialis is a rare multibacillary manifestation of TB that typically occurs in the setting of advanced extracutaneous TB and immunodeficiency:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative terms</strong> – Orificial TB, TB ulcerosa cutis et mucosae.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – TB cutis orificialis develops in individuals with both advanced TB of the gastrointestinal tract, lungs, or genitourinary tract and dramatically impaired cell-mediated immunity [<a href="#rid13">13,23,31,42</a>]. The skin lesions result from the autoinoculation of the mucocutaneous tissues near body orifices by the draining sites of visceral infection [<a href="#rid12">12,24</a>]. TB cutis orificialis most frequently occurs in middle-aged and older adults [<a href="#rid61">61</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>–<strong> </strong>TB cutis orificialis occurs on the oral, nasal, or anogenital skin or mucosa [<a href="#rid12">12,24</a>]. The most frequent oral sites are the distal and lateral tongue; lesions may also involve the palate, lips, or other sites [<a href="#rid12">12,23,75</a>]. </p><p></p><p class="bulletIndent1">A typical lesion appears as a red-yellow nodule that rapidly breaks down to form a painful, circular or irregularly shaped, "punched-out" and friable 1 to 3 cm ulcer  (<a class="graphic graphic_picture graphicRef51950" href="/z/d/graphic/51950.html" rel="external">picture 4</a>) [<a href="#rid12">12,15,31,61</a>]. Ulcers have a pseudomembranous, fibrinous base. Inflammation and edema are often present at the peripheral margins [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>The possibility of TB cutis orificialis should be considered in patients with nonhealing, periorificial ulcers and signs or symptoms suggestive of advanced TB [<a href="#rid60">60</a>]. The detection of AFB in affected tissue via culture, stained smear, or skin biopsy confirms the diagnosis.</p><p></p><p class="bulletIndent1">Histopathologic examination of skin biopsies demonstrates [<a href="#rid3">3,31,61,76</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Easily detectable bacilli in the ulcer walls</p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculoid granulomas at the ulcer edge and in the deep dermis</p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous necrosis</p><p class="bulletIndent2"><span class="glyph">•</span>Intense nonspecific cellular infiltrates</p><p></p><p class="bulletIndent1">Tuberculin skin tests are often negative in patients with TB cutis orificialis due to the associated impairment in host immunity.</p><p></p><p class="bulletIndent1">Because TB cutis orificialis occurs as a consequence of visceral infection, the focus of active extracutaneous TB must be sought as part of the patient evaluation [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/z/d/html/8007.html" rel="external">"Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>–<strong> </strong>Other causes of persistent, periorificial ulcers should be considered during the evaluation of patients with suspected TB cutis orificialis. Examples include aphthous ulcers, lymphogranuloma venereum, syphilis, South American blastomycosis, mucocutaneous leishmaniasis, and cutaneous malignancies, such as squamous cell carcinoma [<a href="#rid3">3,23,61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease course </strong>– The presence of TB cutis orificialis heralds a poor overall prognosis, as patients tend to have severe internal organ disease prior to skin manifestations [<a href="#rid23">23,42</a>]. Without successful treatment of the TB infection, the lesions progress and may eventually contribute to the development of fatal miliary TB [<a href="#rid77">77</a>]. Although resolution within two months after the initiation of treatment has been reported [<a href="#rid77">77-79</a>], other cases may be recalcitrant to treatment [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H22503390"><span class="h3">Lupus vulgaris</span><span class="headingEndMark"> — </span>Lupus vulgaris is<strong> </strong>a chronic and progressive paucibacillary form of cutaneous TB that represents a reactivation of TB infection in people with moderate to high immunity against the bacillus [<a href="#rid3">3,15</a>]. Lupus vulgaris may occasionally occur as a result of direct extension from an underlying focus of infection or via lymphatic or hematogenous spread:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative term</strong> – TB lupus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Lupus vulgaris is considered the most common form of cutaneous TB in Europe and some areas of India [<a href="#rid21">21,41,50,80-83</a>]. In contrast, scrofuloderma appears to be more prevalent in some tropical regions [<a href="#rid17">17,84,85</a>].</p><p></p><p class="bulletIndent1">Lupus vulgaris occurs in individuals of all ages. For unknown reasons, females are two to three times more likely than males to be affected [<a href="#rid23">23</a>]. </p><p></p><p class="bulletIndent1">The development of lupus vulgaris has also been reported in patients with prior TB verrucosa cutis, scrofuloderma, and as a rare complication of BCG vaccination or primary inoculation TB [<a href="#rid39">39,86-90</a>].</p><p></p><p class="bulletIndent1">Although the most common causative organism is <em>M. tuberculosis</em>, there are reported cases caused by <em>M. bovis</em>, and clinical presentation is similar to lupus vulgaris caused by <em>M. tuberculosis</em>. Persons at risk for <em>M. bovis</em> lupus vulgaris are those residing in rural areas, in contact with cattle, and with exposure to infected milk products [<a href="#rid91">91,92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>–<strong> </strong>The clinical findings of lupus vulgaris vary. The classic plaque presentation begins as a collection of discrete, red-brown papules that subsequently coalesce to form an indolent, asymptomatic plaque  (<a class="graphic graphic_picture graphicRef64828" href="/z/d/graphic/64828.html" rel="external">picture 5</a>). The plaque gradually grows peripherally to reach a size of 0.5 to 10 cm and develops central clearing and atrophy. The borders may acquire a serpiginous or verrucous quality.</p><p></p><p class="bulletIndent1">Hypertrophic, ulcerative, and vegetative forms of lupus vulgaris may also occur [<a href="#rid5">5,12,13,58</a>]. Secondarily infected lesions may exhibit a seropurulent discharge and crusting.</p><p></p><p class="bulletIndent1">In Western countries, lupus vulgaris often develops on the head and neck, while in tropical and subtropical areas, lesions are commonly found on the lower extremities or buttocks [<a href="#rid42">42,93</a>]. A multifocal distribution may also occur [<a href="#rid68">68,94</a>].</p><p></p><p class="bulletIndent1">Similar to other granulomatous disorders, such as sarcoidosis and leprosy, diascopy (examination of the lesion under compression with a glass slide) of nonhyperkeratotic areas of lupus vulgaris often reveals a yellow-brown color referred to as an "apple jelly" appearance [<a href="#rid3">3</a>]. However, this finding can be difficult or impossible to appreciate in patients with darkly pigmented skin [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>Lupus vulgaris is a paucibacillary form of cutaneous TB, and mycobacteria often cannot be detected histopathologically or by culture [<a href="#rid12">12</a>]. Information that may be used to support the diagnosis includes consistent clinical and histopathologic features and positive nucleic acid amplification (NAA) test results [<a href="#rid23">23,95</a>]. Tuberculin skin testing is also often positive.</p><p></p><p class="bulletIndent1">Histopathologic examination reveals tuberculoid granulomas with discrete, central caseation in the upper dermis [<a href="#rid42">42,60,61</a>]. The epidermis may be atrophic or acanthotic with excessive hyperkeratosis or pseudoepitheliomatous hyperplasia  (<a class="graphic graphic_picture graphicRef53074" href="/z/d/graphic/53074.html" rel="external">picture 13</a>) [<a href="#rid23">23,31,70</a>]. </p><p></p><p class="bulletIndent1">Dermatoscopy of lupus vulgaris has revealed well-focused, linear-branching telangiectasias on a diffuse or localized, structureless, yellow to orange background and whitish, reticular streaks  (<a class="graphic graphic_picture graphicRef129888" href="/z/d/graphic/129888.html" rel="external">picture 14</a>) [<a href="#rid96">96,97</a>]. Though characteristic of lupus vulgaris, specificity may not be high since this finding may also be seen in cutaneous sarcoidosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>–<strong> </strong>Lupus vulgaris shares clinical features with multiple disorders [<a href="#rid10">10</a>]. Papular lesions should be distinguished from sarcoidosis, colloid milia, acne, and rosacea. Plaques may resemble deep fungal infections, leishmaniasis, late syphilis, yaws, discoid lupus, lymphocytoma cutis, tuberculoid leprosy, pyodermatitis vegetans, and psoriasis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease course </strong>– If untreated, lesions of lupus vulgaris persist and may grow to enormous sizes over the course of years. Ulceration and destruction of underlying tissues, such as the nose, ears, and lips, may occur, causing severe disfigurement [<a href="#rid3">3,12</a>]. (See <a class="local">'Treatment overview'</a> below.)</p><p></p><p class="bulletIndent1">Squamous cell carcinoma occasionally develops in long-standing lesions [<a href="#rid90">90,95,98-100</a>]. Rarely, basal cell carcinoma has occurred in sites of long-standing lupus vulgaris [<a href="#rid101">101,102</a>].</p><p></p><p class="headingAnchor" id="H2729176"><span class="h2">Hematogenous spread</span><span class="headingEndMark"> — </span>Hematogenous transmission of <em>M. tuberculosis</em> from a primary site of infection may lead to metastatic tuberculous abscesses (tuberculous gumma), acute miliary TB, or lupus vulgaris.</p><p class="headingAnchor" id="H22503404"><span class="h3">Metastatic tuberculous abscesses</span><span class="headingEndMark"> — </span>Metastatic tuberculous abscesses, a multibacillary form of cutaneous TB, usually arise as a consequence of hematogenous spread of the bacillus from a primary focus of infection to the subcutaneous tissue during a state of reduced cell-mediated immunity [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative term</strong> – Tuberculous gumma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Metastatic tuberculous abscesses typically occur in malnourished children and immunosuppressed adults [<a href="#rid12">12,31,66</a>]. Immunocompetent adults are infrequently affected; such patients tend to have few lesions [<a href="#rid103">103</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>–<strong> </strong>Patients with metastatic tuberculous abscesses present with single or multiple nontender, fluctuant, subcutaneous nodules. The nodules eventually penetrate the skin, resulting in the formation of ulcers and draining sinuses  (<a class="graphic graphic_picture graphicRef65877" href="/z/d/graphic/65877.html" rel="external">picture 6</a>) [<a href="#rid3">3,16</a>].</p><p></p><p class="bulletIndent1">Lesions may occur at any skin site but frequently develop on the extremities [<a href="#rid66">66</a>]. Associated regional adenopathy usually is not present [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>The diagnosis of metastatic tuberculous abscess is based upon the results of cultures, smears, or skin biopsies that demonstrate the presence of the bacillus.</p><p></p><p class="bulletIndent1">The histopathologic examination is characterized by massive skin necrosis with numerous mycobacterial organisms and may also demonstrate tuberculoid granulomas in the deep dermis [<a href="#rid3">3,31,42</a>].</p><p></p><p class="bulletIndent1">The results of tuberculin skin testing are variable [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>–<strong> </strong>Metastatic tuberculous abscesses share clinical and histologic features with scrofuloderma. However, scrofuloderma occurs as a result of contiguous extension of an infection from an underlying tuberculous focus, rather than hematogenous dissemination [<a href="#rid103">103</a>]. (See <a class="local">'Scrofuloderma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease course </strong>–<strong> </strong>Metastatic tuberculous abscesses are a negative prognostic finding in malnourished and immunosuppressed individuals. Although lesions in immunocompetent individuals may persist for years if untreated, spontaneous resolution can eventually occur [<a href="#rid3">3</a>].</p><p></p><p class="headingAnchor" id="H2729306"><span class="h3">Acute miliary tuberculosis</span><span class="headingEndMark"> — </span>Acute miliary TB is a rare, multibacillary form of TB that results from the hematogenous dissemination of mycobacteria from a primary focus of infection, such as the lung:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative term</strong> – TB cutis miliaris disseminata.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – The disorder typically occurs in infants or individuals with impaired cell-mediated immunity, such as patients with advanced AIDS [<a href="#rid12">12,39</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Most patients with acute miliary TB do not exhibit cutaneous lesions. When present, the cutaneous findings result from bacteremia and are nonspecific [<a href="#rid13">13</a>]. Pinpoint, red-blue or purpuric papules with overlying, tiny vesicles that subsequently become umbilicated and crusted are typically seen. Patients are usually systemically ill, unlike many of the other forms of cutaneous TB.</p><p></p><p class="bulletIndent1">Individual lesions heal over the course of one to four weeks and often resolve with hypopigmented, depressed scars [<a href="#rid12">12</a>]. A cellulitis-like appearance is a rare manifestation of acute miliary TB [<a href="#rid104">104</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Skin biopsies can aid in the diagnosis of acute miliary TB in patients who present with cutaneous lesions. Numerous AFB and abscesses are typically detected [<a href="#rid12">12</a>]. Granulomas may be present in older lesions [<a href="#rid62">62</a>]. The <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> is often negative due to associated anergy.</p><p></p><p>Acute miliary TB is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/8024.html" rel="external">"Clinical manifestations, diagnosis, and treatment of miliary tuberculosis"</a>.)</p><p class="headingAnchor" id="H3761763"><span class="h3">Lupus vulgaris</span><span class="headingEndMark"> — </span>In addition to arising from contiguous spread, lupus vulgaris may also occur as a consequence of hematogenous dissemination of <em>M. tuberculosis</em>. Lupus vulgaris is discussed above. (See <a class="local">'Lupus vulgaris'</a> above.)</p><p class="headingAnchor" id="H22503411"><span class="h1">TUBERCULIDS</span><span class="headingEndMark"> — </span>The pathogenesis of the tuberculids is not fully understood, but they are commonly considered to be cutaneous hypersensitivity eruptions to <em>M. tuberculosis</em> that occur in patients with a moderate or high level of immunity against the organism [<a href="#rid3">3,12,42</a>]. The three main tuberculid disorders are papulonecrotic tuberculid, lichen scrofulosorum, and erythema induratum of Bazin (EIB).</p><p>The following characteristics are consistent with tuberculids [<a href="#rid3">3,31,42,58,60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Failure to detect <em>M. tuberculosis</em> in stains or cultures of affected tissue</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of active or healed extracutaneous <em>M. tuberculosis</em> infection, a strongly positive <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a>, or a positive interferon-gamma release assay [<a href="#rid105">105</a>] (these findings support a history of exposure to the bacillus)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histopathologic evidence for granulomatous inflammation in skin lesions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resolution of skin lesions with anti-TB therapy </p><p></p><p>Although bacilli are usually not detectable in tuberculid lesions, DNA from <em>M. tuberculosis</em> has been detected, albeit inconsistently, in tissue specimens from papulonecrotic tuberculid and EIB [<a href="#rid106">106,107</a>]. This finding offers some support for a role of <em>M. tuberculosis</em> in the pathogenesis of tuberculids.</p><p class="headingAnchor" id="H22503418"><span class="h2">Papulonecrotic tuberculid</span><span class="headingEndMark"> — </span>Papulonecrotic tuberculid is the most common of the tuberculid disorders, first established as a distinct entity by Pautrier in 1936 [<a href="#rid108">108</a>]. Papulonecrotic tuberculid may coexist with other tuberculids, lupus vulgaris, and scrofuloderma [<a href="#rid108">108-115</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Papulonecrotic tuberculid is most frequently seen in children and young adults [<a href="#rid116">116</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>–<strong> </strong>Papulonecrotic tuberculid typically presents as an asymptomatic, symmetric, and recurring eruption of 2 to 8 mm, firm, dark red or violaceous papules that subsequently become pustular or necrotic  (<a class="graphic graphic_picture graphicRef74606 graphicRef55062" href="/z/d/graphic/74606.html" rel="external">picture 7A-B</a>). Lesions most commonly occur on the face, ears, extensor extremities, and buttocks [<a href="#rid15">15,23,31,61,66,108</a>]. </p><p></p><p class="bulletIndent1">Fever and constitutional symptoms may precede the appearance of skin lesions [<a href="#rid24">24,60</a>], and associated lymphadenitis is common [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>The presence of consistent clinical and histopathologic findings and evidence for TB infection supports the diagnosis of papulonecrotic tuberculid. </p><p></p><p class="bulletIndent1">Histopathologic examination often demonstrates wedge-shaped necrosis in the upper dermis and epidermis and nonspecific or tuberculoid granulomatous inflammation. Vascular involvement is a cardinal feature seen as obliterative or granulomatous vasculitis [<a href="#rid23">23,31,116</a>]<em>. M. tuberculosis</em> bacilli are not usually detectable via microscopy or cultures. </p><p></p><p class="bulletIndent1">In addition to the typical histopathologic findings, data that can support the diagnosis include a positive <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> or interferon-gamma release assay, a detectable extracutaneous focus of TB infection, the detection of mycobacterial DNA in lesional tissue [<a href="#rid106">106,116,117</a>], and a positive response to anti-TB therapy. An extracutaneous focus of TB (eg, cervical lymph nodes, lungs, or other sites) is detectable in 38 to 75 percent of patients [<a href="#rid118">118</a>]. In a series of 12 patients with papulonecrotic tuberculid, mycobacterial DNA was detected by polymerase chain reaction (PCR) in 11 of 22 biopsy specimens [<a href="#rid106">106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>–<strong> </strong>The differential diagnosis of papulonecrotic tuberculid includes papular disorders that may present with necrotic or excoriated papules. Examples include pityriasis lichenoides et varioliformis acuta (PLEVA), prurigo, secondary syphilis, varicella, lymphomatoid papulosis, perforating disorders, leukocytoclastic vasculitis, and eosinophilic granulomatosis with polyangiitis [<a href="#rid10">10,23,31,39,61</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course </strong>–<strong> </strong>Lesions may spontaneously resolve over the course of several weeks, leaving residual, pitted or varioliform scars. However, recurrence is common, and if untreated, papulonecrotic tuberculid may persist for years [<a href="#rid24">24,31,60,118</a>].</p><p></p><p class="bulletIndent1">Patients typically improve within days to weeks of the initiation of anti-TB therapy [<a href="#rid117">117,119</a>]. (See <a class="local">'Treatment overview'</a> below.)</p><p></p><p class="headingAnchor" id="H22503425"><span class="h2">Lichen scrofulosorum</span><span class="headingEndMark"> — </span>Lichen scrofulosorum is a rare tuberculid:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Lichen scrofulosorum most frequently occurs in children and young adults with nodal, pulmonary, skeletal, or intracranial TB [<a href="#rid3">3,12,42,120,121</a>]. Lichen scrofulosorum has also been reported after Bacille Calmette-Guérin (BCG) vaccination and in association with <em>Mycobacterium avium-intracellulare</em> infection [<a href="#rid122">122-125</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>–<strong> </strong>Lichen scrofulosorum presents with crops of firm, 1 to 5 mm, asymptomatic, grouped, yellow-red to brown-red papules  (<a class="graphic graphic_picture graphicRef63717" href="/z/d/graphic/63717.html" rel="external">picture 8</a>). Lesions tend to be follicular or perifollicular and are most often found on the trunk [<a href="#rid3">3,23,24,60,61,121,126</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>Similar to papulonecrotic tuberculid, the diagnosis of lichen scrofulosorum is based upon a consistent clinical picture in the context of concordant histopathologic findings and evidence for TB infection. The <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> is often strongly positive [<a href="#rid42">42,121</a>]. A positive interferon-gamma release assay can also support the presence of a tuberculous focus.</p><p></p><p class="bulletIndent1">Histopathologic examination reveals tuberculoid granulomas in the upper dermis as well as around hair follicles and eccrine glands. Acid-fast bacilli (AFB) are not detected [<a href="#rid23">23,31,42,70</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>–<strong> </strong>Other papular disorders may present with lesions that resemble lichen scrofulosorum. As examples, lichen planus, lichenoid secondary syphilis, papular eczema, lichen nitidus, lichen spinulosus, pityriasis rubra pilaris, and papular sarcoidosis should be considered in the differential diagnosis [<a href="#rid10">10,23,31,39,61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course</strong> – Without treatment, lesions spontaneously resolve without scarring after several months to several years [<a href="#rid12">12</a>]. Anti-TB treatment usually leads to complete resolution within weeks [<a href="#rid23">23</a>]. (See <a class="local">'Treatment overview'</a> below.)</p><p></p><p class="headingAnchor" id="H22503432"><span class="h2">Erythema induratum of Bazin</span><span class="headingEndMark"> — </span>The terms "erythema induratum of Bazin" (EIB) and "nodular vasculitis" are used to refer to a granulomatous, lobular panniculitis of the lower extremities that may develop in association with a variety of disorders, particularly infections [<a href="#rid107">107,127</a>]. Bazin first described this entity in 1855, with the belief of TB as the origin. (See  <a class="medical medical_review" href="/z/d/html/109264.html" rel="external">"Erythema induratum (nodular vasculitis)"</a>.)</p><p>Although the two terms are often used interchangeably to refer to this presentation, some authors have preferably utilized the term EIB to refer to TB-associated lesions [<a href="#rid107">107,128</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Young women and middle-aged women are most commonly affected [<a href="#rid127">127</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– EIB classically presents with the development of mildly tender, dull red, subcutaneous nodules on the lower legs over the course of several weeks. The lesions are symmetrically distributed and most commonly located on the posterior aspects of the lower legs and may be up to several centimeters in diameter [<a href="#rid107">107,127</a>]. Breakdown of the nodules often occurs, leading to the formation of deep, draining ulcers  (<a class="graphic graphic_picture graphicRef76526 graphicRef53596 graphicRef64335" href="/z/d/graphic/76526.html" rel="external">picture 9A-C</a>).</p><p></p><p class="bulletIndent1">Associated findings may include erythrocyanosis, chronic venous insufficiency, livedo reticularis, and lower limb edema. Sclerosis may ensue [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>The diagnosis of TB-associated EIB is made based upon recognition of the clinical features, histopathologic findings, and evidence for <em>M. tuberculosis</em> infection (eg, history of TB, a detectable focus of infection, a positive <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> or interferon-gamma release assay, or improvement with TB therapy) [<a href="#rid14">14,107,129-131</a>]. Mycobacterial DNA can be detected by PCR in 14 to 77 percent of biopsy specimens [<a href="#rid107">107</a>]. </p><p></p><p class="bulletIndent1">Since EIB is a form of panniculitis, a biopsy that obtains an adequate sample of the subcutaneous fat is essential for histopathologic examination. An excisional wedge biopsy is the preferred procedure. The tissue specimen usually reveals [<a href="#rid62">62</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lobular or mixed lobular and septal panniculitis</p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculoid or poorly formed granulomas</p><p class="bulletIndent2"><span class="glyph">•</span>Mixed inflammatory infiltrate with neutrophils, lymphocytes, and plasma cells</p><p class="bulletIndent2"><span class="glyph">•</span>Fat necrosis</p><p></p><p class="bulletIndent1">Vascular changes are also usually present; in some cases, necrotizing vasculitis is seen. AFB are not typically detected [<a href="#rid3">3,42</a>].</p><p></p><p class="bulletIndent1">If an association with TB is not found in a patient with skin lesions consistent with this disorder, other potential causes should be investigated. (See  <a class="medical medical_review" href="/z/d/html/109264.html" rel="external">"Erythema induratum (nodular vasculitis)", section on 'Associated disorders'</a> and  <a class="medical medical_review" href="/z/d/html/109264.html" rel="external">"Erythema induratum (nodular vasculitis)", section on 'Additional studies'</a>.).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>–<strong> </strong>Similar to EIB, nodules due to erythema nodosum primarily occur on the lower legs. However, in contrast to EIB, lesions of erythema nodosum are more likely to occur on the anterior legs, do not ulcerate, and demonstrate a septal panniculitis on histopathologic examination. (See  <a class="medical medical_review" href="/z/d/html/5612.html" rel="external">"Erythema nodosum"</a>.)</p><p></p><p class="bulletIndent1">Other disorders to consider include polyarteritis nodosa, subcutaneous sarcoidosis, tertiary syphilis, and other panniculitides [<a href="#rid31">31,132,133</a>]. (See  <a class="medical medical_review" href="/z/d/html/109264.html" rel="external">"Erythema induratum (nodular vasculitis)", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course </strong>–<strong> </strong>Although individual lesions spontaneously resolve over the course of several weeks to a few months, leaving scars and postinflammatory hyperpigmentation [<a href="#rid127">127</a>], recurrences may occur every three to four months [<a href="#rid107">107</a>]. Lymphedema or elephantiasis nostra may develop with frequent recurrences [<a href="#rid132">132</a>].</p><p></p><p class="bulletIndent1">EIB typically responds to anti-TB medical therapy [<a href="#rid107">107,127</a>]. Other agents that have been used for the management of EIB/nodular vasculitis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/109264.html" rel="external">"Erythema induratum (nodular vasculitis)", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H3763762"><span class="h2">Other</span><span class="headingEndMark"> — </span>Nodular tuberculid is a tuberculid disorder that has been reported in several patients [<a href="#rid134">134,135</a>]. Similar to EIB, patients present with nodules on the lower legs. However, in contrast to EIB, granulomatous inflammation occurs at the junction of the dermis and subcutaneous fat, rather than primarily within the panniculus. In addition, the lesions do not tend to ulcerate.</p><p class="headingAnchor" id="H2478555009"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of patients with cutaneous manifestations of TB includes assessment for other sites of active TB infection and the initiation of anti-TB therapy.</p><p class="headingAnchor" id="H512501549"><span class="h2">Evaluation for extracutaneous involvement</span><span class="headingEndMark"> — </span>A diagnosis of a cutaneous manifestation of TB should prompt an assessment for extracutaneous TB infection, as the presence of active extracutaneous TB is common. This generally includes at least a review of systems, physical examination, and chest radiograph. Additional evaluation is guided by these findings. (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)", section on 'Excluding TB disease'</a> and  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8020.html" rel="external">"Tuberculosis infection (latent tuberculosis) in children", section on 'Excluding TB disease'</a> and  <a class="medical medical_review" href="/z/d/html/8007.html" rel="external">"Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H606441"><span class="h2">Treatment overview</span><span class="headingEndMark"> — </span>The general approach to treatment of cutaneous TB is the same as the approach to systemic TB, consisting of a course of systemic, multidrug anti-TB therapy [<a href="#rid15">15,24,31,39,42,60,136</a>]. Occasionally, surgical procedures are performed as an adjunct to systemic therapy. Special considerations for the treatment of erythema induratum of Bazin (EIB) are reviewed separately (see  <a class="medical medical_review" href="/z/d/html/109264.html" rel="external">"Erythema induratum (nodular vasculitis)", section on 'Treatment'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic therapy</strong> – In general, systemic anti-TB therapy consists of an initial bactericidal phase to induce a rapid reduction in the number of bacteria and is followed by a longer treatment phase designed to eradicate any remaining bacteria [<a href="#rid3">3,12,137</a>]. The choice of a specific regimen is influenced by patient comorbidities and immune status, as well as local mycobacterial resistance patterns. Drug treatment regimens for TB are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a> and  <a class="medical medical_review" href="/z/d/html/135189.html" rel="external">"Tuberculosis disease in children: Treatment and prevention"</a>.)</p><p></p><p class="bulletIndent1">Every effort should be made to culture the organism for sensitivity testing to identify patients requiring an alternative approach to therapy.</p><p></p><p class="bulletIndent1">The response to treatment of cutaneous lesions can be assessed through physical examination. In general, treatment should be continued for at least two months following the complete resolution of skin lesions.</p><p></p><p class="bulletIndent1">As with pulmonary TB, patients with cutaneous TB are at risk for paradoxical worsening of cutaneous TB in association with the development of the immune reconstitution inflammatory syndrome (IRIS) after the initiation of antiretroviral therapy. The features, management, and prevention of IRIS are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome", section on 'Tuberculosis'</a> and  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy", section on 'Preventing IRIS'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong> – Surgical intervention is not routinely utilized for the management of cutaneous TB but is sometimes employed as an adjunct to pharmacologic therapy [<a href="#rid138">138</a>].</p><p></p><p class="bulletIndent1">Surgical excision has been utilized in the management of extensive or recalcitrant scrofuloderma. In addition, surgical excision, cauterization, and cryosurgery have been performed to hasten the resolution of small, early lesions of TB verrucosa cutis and lupus vulgaris.</p><p></p><p class="bulletIndent1">Reconstructive plastic surgery after treatment can be beneficial for patients with destructive lesions of lupus vulgaris [<a href="#rid24">24,138</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – The efficacy and safety of topical <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, an experimental drug, for cutaneous TB is under investigation [<a href="#rid139">139,140</a>].</p><p></p><p class="headingAnchor" id="H3763973"><span class="h1">ASSOCIATED DISORDERS</span></p><p class="headingAnchor" id="H3763980"><span class="h2">Bacille Calmette-Guérin vaccination reactions</span><span class="headingEndMark"> — </span>The Bacille Calmette-Guérin (BCG) vaccine is composed of a live, attenuated strain of <em>M. bovis</em> that is used in many parts of the world to enhance immunity to TB. Rarely, dermatologic complications of BCG vaccination occur. Local tissue reactions, ulceration, abscess formation, and suppurated lymphadenitis are most common [<a href="#rid13">13,30</a>], but scrofuloderma, lupus vulgaris, erythema induratum of Bazin (EIB), papulonecrotic tuberculid, and lichen scrofulosorum-like lesions have been described [<a href="#rid23">23,31,122,141</a>]. </p><p>The time frame from vaccination to the development of skin lesions ranges from several months to years. The clinical presentation depends upon the patient's inherent susceptibility, virulence of bacillus, inoculum size, and technique [<a href="#rid142">142</a>]. (See  <a class="medical medical_review" href="/z/d/html/8022.html" rel="external">"Prevention of tuberculosis: BCG immunization and nutritional supplementation", section on 'Safety and adverse effects'</a>.)</p><p class="headingAnchor" id="H544489945"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111822.html" rel="external">"Society guideline links: Diagnosis and treatment of tuberculosis"</a>.)</p><p class="headingAnchor" id="H3764525"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – Tuberculosis (TB) is a mycobacterial infection that can affect multiple organ systems. <em>Mycobacterium tuberculosis</em>, an acid-fast bacillus, is the primary inciting organism of cutaneous manifestations of TB. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Cutaneous manifestations of TB are commonly divided into two groups: true cutaneous TB and tuberculids. (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>True cutaneous tuberculosis</strong> – True cutaneous TB includes conditions in which cutaneous lesions are a direct manifestation of infection at the site of the skin lesions. True cutaneous TB may result from direct entry of the mycobacterium into the skin or from local or hematogenous spread of <em>M. tuberculosis</em> from an endogenous focus. The immune response of the host to <em>M. tuberculosis</em> is an important factor in the development of cutaneous TB. (See <a class="local">'True cutaneous tuberculosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberculids</strong> – The tuberculids are a group of cutaneous disorders that may reflect hypersensitivity reactions to <em>M. tuberculosis</em> antigens. The three main subtypes of tuberculids are papulonecrotic tuberculid, lichen scrofulosorum, and erythema induratum of Bazin (EIB). Organisms are not usually detectable in cultures, smears, or pathology specimens taken from tuberculid skin lesions. (See <a class="local">'Tuberculids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A variety of diagnostic studies are used for the evaluation of patients with suspected cutaneous manifestations of TB. Mycobacterial cultures represent the gold standard for confirming active infection. Other studies that may be utilized for patient evaluation include stained smears, histopathologic evaluation, tuberculin skin tests, interferon-gamma release assays, and nucleic acid amplification (NAA) tests. (See <a class="local">'Diagnostic approach'</a> above.)</p><p></p><p class="bulletIndent1">Given the plethora of cutaneous manifestations of TB, a high index of suspicion is of utmost importance in making the correct diagnosis. (See <a class="local">'True cutaneous tuberculosis'</a> above and <a class="local">'Tuberculids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Systemic treatment with multidrug therapy is the cornerstone of treatment of cutaneous manifestations of TB. (See <a class="local">'Treatment overview'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization. Global tuberculosis report, 2019. https://www.who.int/tb/publications/global_report/en/ (Accessed on March 23, 2020).</li><li class="breakAll">Laennec RT. Traité de l'Auscultation Médiate Et des Maladies des Poumons Et du Coeur, Asselin and Cie, 1826. p.649.</li><li><a class="nounderline abstract_t">MacGregor RR. Cutaneous tuberculosis. Clin Dermatol 1995; 13:245.</a></li><li><a class="nounderline abstract_t">MICHELSON HE. The history of lupus vulgaris. J Invest Dermatol 1946; 7:261.</a></li><li><a class="nounderline abstract_t">van Zyl L, du Plessis J, Viljoen J. Cutaneous tuberculosis overview and current treatment regimens. Tuberculosis (Edinb) 2015; 95:629.</a></li><li><a class="nounderline abstract_t">Jayanthi NG, Anandan V, Kopika S. Various presentations of cutaneous tuberculosis at a tertiary care centre: a one year prospective study. Int J Res Dermatol 2018; 4:559.</a></li><li><a class="nounderline abstract_t">Tshisevhe V, Mbelle N, Peters RP. Cutaneous tuberculosis in HIV-infected individuals: lessons learnt from a case series. South African J HIV Med 2018; 20:a895.</a></li><li><a class="nounderline abstract_t">Mwiru RS, Nagu TJ, Kaduri P, et al. Prevalence and factors associated with alcohol drinking among HIV and tuberculosis co-infected patients in Dar es Salaam, Tanzania. AIDS Care 2018; 30:173.</a></li><li><a class="nounderline abstract_t">Ankrah AO, Glaudemans AWJM, Maes A, et al. Tuberculosis. Semin Nucl Med 2018; 48:108.</a></li><li><a class="nounderline abstract_t">Chen Q, Chen W, Hao F. Cutaneous tuberculosis: A great imitator. Clin Dermatol 2019; 37:192.</a></li><li><a class="nounderline abstract_t">van Soolingen D, Hoogenboezem T, de Haas PE, et al. A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa. Int J Syst Bacteriol 1997; 47:1236.</a></li><li><a class="nounderline abstract_t">Barbagallo J, Tager P, Ingleton R, et al. Cutaneous tuberculosis: diagnosis and treatment. Am J Clin Dermatol 2002; 3:319.</a></li><li><a class="nounderline abstract_t">Dias MF, Bernardes Filho F, Quaresma MV, et al. Update on cutaneous tuberculosis. An Bras Dermatol 2014; 89:925.</a></li><li><a class="nounderline abstract_t">Sethuraman G, Ramesh V. Cutaneous tuberculosis in children. Pediatr Dermatol 2013; 30:7.</a></li><li><a class="nounderline abstract_t">Handog EB, Gabriel TG, Pineda RT. Management of cutaneous tuberculosis. Dermatol Ther 2008; 21:154.</a></li><li><a class="nounderline abstract_t">Singal A, Kaur I, Jakhar D, et al. Clinicoepidemiological characteristics of cutaneous tuberculosis in 1458 Indian patients: a retrospective analytical study from a tertiary care center. Int J Dermatol 2022; 61:1012.</a></li><li><a class="nounderline abstract_t">Bravo FG, Gotuzzo E. Cutaneous tuberculosis. Clin Dermatol 2007; 25:173.</a></li><li><a class="nounderline abstract_t">Punia RS, Aggarwal P, Kundu R, et al. Cutaneous tuberculosis: A clinicopathological study of 50 cases from a tertiary care referral hospital. Appl Med Res 2015; 1.</a></li><li><a class="nounderline abstract_t">Dwari BC, Ghosh A, Paudel R, Kishore P. A clinicoepidemiological study of 50 cases of cutaneous tuberculosis in a tertiary care teaching hospital in pokhara, Nepal. Indian J Dermatol 2010; 55:233.</a></li><li><a class="nounderline abstract_t">Chaudhari ND, Talaniker HV, Deshmukh P, Supta S. A clinicopathological study of cutaneous tuberculosis at Pune district, Maharashtra. Int J Pharm Biomed 2012; 3:181.</a></li><li><a class="nounderline abstract_t">Puri N. A clinical and histopathological profile of patients with cutaneous tuberculosis. Indian J Dermatol 2011; 56:550.</a></li><li class="breakAll">Khanna N. Illustrated Synopsis of Dermatology and Sexually Transmitted Diseases, 3rd ed, Elsevier, 2009. p.217.</li><li class="breakAll">Sethi A. Tuberculosis and infections with atypical mycobacteria. In: Fiztpatrick's Dermatology, 9th ed, Kang S, Amagai M, Bruckner AL, et al (Eds), McGraw-Hill Education, 2019. p.2858.</li><li class="breakAll">Handog EB, Ramam M, Gabriel MT, Suthar C. Skin tuberculosis in South Asia. In: Asian Skin and Skin Diseases, Eun HC, Kim SC, Lee WS (Eds), MEDrang Inc, 2011. p.349.</li><li class="breakAll">Weedon D. Cutaneous infections and infestations - histological patterns. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.544.</li><li class="breakAll">"Report of an Expert Consultation on the Uses of Nucleic Acid Amplification Tests for the Diagnosis of Tuberculosis." Centers for Disease Control and Prevention. https://npin.cdc.gov/publication/report-expert-consultation-uses-nucleic-acid-amplification-tests-diagnosis-tuberculosis (Accessed on July 25, 2020).</li><li><a class="nounderline abstract_t">Peralta G, Barry P, Pascopella L. Use of Nucleic Acid Amplification Tests in Tuberculosis Patients in California, 2010-2013. Open Forum Infect Dis 2016; 3:ofw230.</a></li><li><a class="nounderline abstract_t">Maldonado-Bernal C, Ramos-Garibay A, Rios-Sarabia N, et al. Nested Polymerase Chain Reaction and Cutaneous Tuberculosis. Am J Dermatopathol 2019; 41:428.</a></li><li><a class="nounderline abstract_t">Khadka P, Koirala S, Thapaliya J. Cutaneous Tuberculosis: Clinicopathologic Arrays and Diagnostic Challenges. Dermatol Res Pract 2018; 2018:7201973.</a></li><li><a class="nounderline abstract_t">Zhu B, Dockrell HM, Ottenhoff THM, et al. Tuberculosis vaccines: Opportunities and challenges. Respirology 2018; 23:359.</a></li><li class="breakAll">James WD, Berger TG, Elston DM. Andrews' Diseases of the Skin Clinical Dermatology, 11th ed, Elsevier, 2011. p.322.</li><li><a class="nounderline abstract_t">Birhanu T, Ejeta E. Review on convectional and advanced diagnostic techniques of human tuberculosis (TB) in Ethiopia. J Med Lab Diagn 2015; 6:9.</a></li><li><a class="nounderline abstract_t">Franco-Paredes C, Marcos LA, Henao-Martínez AF, et al. Cutaneous Mycobacterial Infections. Clin Microbiol Rev 2018; 32.</a></li><li><a class="nounderline abstract_t">Nischal U, Nischal Kc, Khopkar U. Techniques of skin biopsy and practical considerations. J Cutan Aesthet Surg 2008; 1:107.</a></li><li><a class="nounderline abstract_t">Regatieri A, Abdelwahed Y, Perez MT, Bush LM. Testing for tuberculosis: the roles of tuberculin skin tests and interferon gamma release assays. Lab Investigation 2011; 42:1.</a></li><li><a class="nounderline abstract_t">Kandi V. Revisiting Mantoux test in the era of immunization and Multi-drug resistant tuberculosis (MDR-TB). Appl Med Res 2015; 1:26.</a></li><li><a class="nounderline abstract_t">Santos JB, Figueiredo AR, Ferraz CE, et al. Cutaneous tuberculosis: diagnosis, histopathology and treatment - part II. An Bras Dermatol 2014; 89:545.</a></li><li><a class="nounderline abstract_t">Lai CC, Tan CK, Lin SH, et al. Diagnostic value of an enzyme-linked immunospot assay for interferon-γ in cutaneous tuberculosis. Diagn Microbiol Infect Dis 2011; 70:60.</a></li><li><a class="nounderline abstract_t">Tirado-Sanchez A, Bonifaz A. Cutaneous Tuberculosis: a Review of the Current Literature. Curr Trop Med Rep 2018; 5:67.</a></li><li><a class="nounderline abstract_t">Acharya B, Acharya A, Gautam S, et al. Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis. Mol Biol Rep 2020; 47:4065.</a></li><li><a class="nounderline abstract_t">Lall H, Singh NP, Chaudhary M, Kaur IR. Comparison of conventional and molecular methods in diagnosis of extrapulmonary (cutaneous) tuberculosis in a tertiary care hospital in Delhi. Int J Med Sci Pub Health 2017; 6:102.</a></li><li><a class="nounderline abstract_t">Frankel A, Penrose C, Emer J. Cutaneous tuberculosis: a practical case report and review for the dermatologist. J Clin Aesthet Dermatol 2009; 2:19.</a></li><li><a class="nounderline abstract_t">Tan SH, Tan BH, Goh CL, et al. Detection of Mycobacterium tuberculosis DNA using polymerase chain reaction in cutaneous tuberculosis and tuberculids. Int J Dermatol 1999; 38:122.</a></li><li><a class="nounderline abstract_t">Pai M. The accuracy and reliability of nucleic acid amplification tests in the diagnosis of tuberculosis. Natl Med J India 2004; 17:233.</a></li><li><a class="nounderline abstract_t">Hernández Solis A, Herrera González NE, Cazarez F, et al. Skin biopsy: a pillar in the identification of cutaneous Mycobacterium tuberculosis infection. J Infect Dev Ctries 2012; 6:626.</a></li><li><a class="nounderline abstract_t">Tan SH, Tan HH, Sun YJ, Goh CL. Clinical utility of polymerase chain reaction in the detection of Mycobacterium tuberculosis in different types of cutaneous tuberculosis and tuberculids. Ann Acad Med Singapore 2001; 30:3.</a></li><li><a class="nounderline abstract_t">Hsiao PF, Tzen CY, Chen HC, Su HY. Polymerase chain reaction based detection of Mycobacterium tuberculosis in tissues showing granulomatous inflammation without demonstrable acid-fast bacilli. Int J Dermatol 2003; 42:281.</a></li><li><a class="nounderline abstract_t">Arora SK, Kumar B, Sehgal S. Development of a polymerase chain reaction dot-blotting system for detecting cutaneous tuberculosis. Br J Dermatol 2000; 142:72.</a></li><li><a class="nounderline abstract_t">Padmavathy L, Rao L, Veliath A. Utility of polymerase chain reaction as a diagnostic tool in cutaneous tuberculosis. Indian J Dermatol Venereol Leprol 2003; 69:214.</a></li><li><a class="nounderline abstract_t">Suthar C, Rana T, Singh UB, et al. mRNA and DNA PCR tests in cutaneous tuberculosis. Indian J Dermatol Venereol Leprol 2013; 79:65.</a></li><li><a class="nounderline abstract_t">Ramam M, Mittal R, Ramesh V. How soon does cutaneous tuberculosis respond to treatment? Implications for a therapeutic test of diagnosis. Int J Dermatol 2005; 44:121.</a></li><li><a class="nounderline abstract_t">Ramam M, Tejasvi T, Manchanda Y, et al. What is the appropriate duration of a therapeutic trial in cutaneous tuberculosis? Further observations. Indian J Dermatol Venereol Leprol 2007; 73:243.</a></li><li><a class="nounderline abstract_t">Pai K, Baliga P, Pai S, Monappa V. Tattoo induced cutaneous tuberculosis: a rare occurrence. Ind J Appl Res 2015; 5:860.</a></li><li><a class="nounderline abstract_t">Kim JK, Kim TY, Kim DH, Yoon MS. Three cases of primary inoculation tuberculosis as a result of illegal acupuncture. Ann Dermatol 2010; 22:341.</a></li><li><a class="nounderline abstract_t">Afsar FS, Ozcelik S, Uysal SS, et al. Primary inoculation tuberculosis: a report of a rare entity. Rev Soc Bras Med Trop 2015; 48:112.</a></li><li><a class="nounderline abstract_t">Sehgal VN. Cutaneous tuberculosis. Dermatol Clin 1994; 12:645.</a></li><li><a class="nounderline abstract_t">Kluger N. [Cutaneous infections related to permanent tattooing]. Med Mal Infect 2011; 41:115.</a></li><li><a class="nounderline abstract_t">Scollard DM, Dacso MM, Abad-Venida ML. Tuberculosis and Leprosy: Classical Granulomatous Diseases in the Twenty-First Century. Dermatol Clin 2015; 33:541.</a></li><li><a class="nounderline abstract_t">Nakamura S, Hashimoto Y, Nishi K, et al. Cutaneous tuberculosis simulating lymphocutaneous sporotrichosis. Australas J Dermatol 2012; 53:316.</a></li><li class="breakAll">Ramam M. Cutaneous tuberculosis. In: Tuberculosis, 2nd ed, Sharma SK, Mohan A (Eds), Jaypee Brothers, 2009. p.384.</li><li class="breakAll">Nascimento LV. Tuberculosis. In: Tropical Dermatology, Tyring SK, Lupi O, Hengge UR (Eds), Churchill Livingstone, 2005. p.251.</li><li class="breakAll">Weedon D. Bacterial and rickettsial infections. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.547.</li><li><a class="nounderline abstract_t">Karoney MJ, Kaumbuki EK, Koech MK, Lelei LK. Primary cutaneous tuberculosis in a 27-year-old medical intern from needle-stick injury: a case report. Clin Case Rep 2015; 3:39.</a></li><li class="breakAll">Nascimento LV, Neves RG. Tuberculose cutanea. In: Dermatologia Tropical, Talhart S, Neves RG (Eds), MEDSI, 1995. p.267.</li><li><a class="nounderline abstract_t">Sehgal VN, Sehgal R, Bajaj P, et al. Tuberculosis verrucosa cutis (TBVC). J Eur Acad Dermatol Venereol 2000; 14:319.</a></li><li class="breakAll">Arenas R. Cutaneous tuberculosis. In: Tropical Dermatology, Arenas R, Estrada R (Eds), Landes Bioscience, 2001. p.132.</li><li><a class="nounderline abstract_t">Gruber PC, Whittam LR, du Vivier A. Tuberculosis verrucosa cutis on the sole of the foot. Clin Exp Dermatol 2002; 27:188.</a></li><li><a class="nounderline abstract_t">Aruna C, Senthil Kumar AL, Sridevi K, et al. A clinicoepidemiological study of cutaneous tuberculosis in a tertiary care teaching hospital in Andhra Pradesh, India. Int J Res Dermatol 2017; 3:88.</a></li><li><a class="nounderline abstract_t">Kim G, Jeong YI, Huh JW, et al. Interferon-gamma release assay in a patient with tuberculosis verrucosa cutis. Ann Dermatol 2015; 27:109.</a></li><li><a class="nounderline abstract_t">Agrawal R, Kumar M, Kumar P. Cutaneous tuberculosis- a clinico-histopathological study. Ind J Med Spec 2012; 3:138.</a></li><li><a class="nounderline abstract_t">Müller H, Eisendle K, Zelger B, Zangerle R. Bilateral scrofuloderma of the axilla masquerading as hidradenitis suppurativa. Acta Derm Venereol 2008; 88:629.</a></li><li><a class="nounderline abstract_t">Tan H, Karakuzu A, Arik A. Scrofuloderma after BCG vaccination. Pediatr Dermatol 2002; 19:323.</a></li><li><a class="nounderline abstract_t">Rao AG. Scrofuloderma associated with tuberculosis verrucosa cutis. Indian J Dermatol Venereol Leprol 2014; 80:76.</a></li><li><a class="nounderline abstract_t">Sethuraman G, Kaur J, Nag HL, et al. Symmetrical scrofuloderma with tuberculosis verrucosa cutis. Clin Exp Dermatol 2006; 31:475.</a></li><li><a class="nounderline abstract_t">Mansfield BS, Pieton K. Tuberculosis Cutis Orificialis. Open Forum Infect Dis 2019; 6:ofz428.</a></li><li><a class="nounderline abstract_t">Brown FS, Anderson RH, Burnett JW. Cutaneous tuberculosis. J Am Acad Dermatol 1982; 6:101.</a></li><li><a class="nounderline abstract_t">Leon-Mateos A, Sánchez-Aguilar D, Lado F, Toribio J. Perianal ulceration: a case of tuberculosis cutis orificialis. J Eur Acad Dermatol Venereol 2005; 19:364.</a></li><li><a class="nounderline abstract_t">Choi SR, Kim JK, Kim DH, Yoon MS. A case of tuberculosis cutis orificialis with perianal involvement. Ann Dermatol 2009; 21:443.</a></li><li><a class="nounderline abstract_t">Yueh LH, Loo LY, Hoon TS, Hee TH. Persistent perianal ulcers. Tuberculosis cutis orificialis (TCO). Arch Dermatol 2009; 145:931.</a></li><li><a class="nounderline abstract_t">Kumar B, Muralidhar S. Cutaneous tuberculosis: a twenty-year prospective study. Int J Tuberc Lung Dis 1999; 3:494.</a></li><li><a class="nounderline abstract_t">Patra AC, Gharami RC, Banerjee PK. A profile of cutaneous tuberculosis. Indian J Dermatol 2006; 51:105.</a></li><li><a class="nounderline abstract_t">Srinivas T, Girisha BS, Srinivas H. A ten year prospective clinicopathological study of cutaneous tuberculosis at a tertiary care hospital in coastal Karnataka. Int J Clin Exp Dermatol 2017; 3:17.</a></li><li><a class="nounderline abstract_t">Singh EN, Purohit S, Agarwal US, et al. Clinico-epidemiological study of cutaneous tuberculosis in a tertiary care hospital of Rajasthan. IMJH 2017; 3:317.</a></li><li><a class="nounderline abstract_t">Kivanç-Altunay I, Baysal Z, Ekmekçi TR, Köslü A. Incidence of cutaneous tuberculosis in patients with organ tuberculosis. Int J Dermatol 2003; 42:197.</a></li><li><a class="nounderline abstract_t">Saher N, Wahid Z, Ahmed I, et al. Clinical presentations of cutaneous tuberculosis. J Pak Assoc Dermatol 2014; 24:132.</a></li><li><a class="nounderline abstract_t">Marcoval J, Servitje O, Moreno A, et al. Lupus vulgaris. Clinical, histopathologic, and bacteriologic study of 10 cases. J Am Acad Dermatol 1992; 26:404.</a></li><li><a class="nounderline abstract_t">HORWITZ O, MEYER J. The safety record of BCG vaccination and untoward reactions observed after vaccination. Bibl Tuberc 1957; 13:245.</a></li><li><a class="nounderline abstract_t">HARTSTON W. Uncommon skin reactions after BCG vaccination. Tubercle 1959; 40:265.</a></li><li><a class="nounderline abstract_t">Fariña MC, Gegundez MI, Piqué E, et al. Cutaneous tuberculosis: a clinical, histopathologic, and bacteriologic study. J Am Acad Dermatol 1995; 33:433.</a></li><li><a class="nounderline abstract_t">Sellami K, Boudaya S, Chaabane H, et al. Twenty-nine cases of lupus vulgaris. Med Mal Infect 2016; 46:93.</a></li><li><a class="nounderline abstract_t">Jaka-Moreno A, López-Núñez M, López-Pestaña A, Tuneu-Valls A. [Lupus vulgaris caused by Mycobacterium bovis]. Actas Dermosifiliogr 2012; 103:251.</a></li><li><a class="nounderline abstract_t">Litaiem N, Youssef S, Jaber K, et al. Unusual clinical presentation of cutaneous tuberculosis caused by Mycobacterium bovis. J Dermatolog Clin Res 2014; 2:1010.</a></li><li><a class="nounderline abstract_t">Can B, Zindanci I, Turkoglu Z, et al. Disseminated lupus vulgaris: A case report. North Clin Istanbul 2014; 1:53.</a></li><li><a class="nounderline abstract_t">Murugan S, Vetrichevvel T, Subramanyam S, Subramanian A. Childhood multicentric lupus vulgaris. Indian J Dermatol 2011; 56:343.</a></li><li><a class="nounderline abstract_t">Ljubenovic MS, Ljubenovic DB, Binic II, et al. Cutaneous tuberculosis and squamous-cell carcinoma. An Bras Dermatol 2011; 86:541.</a></li><li><a class="nounderline abstract_t">Micali G, Lacarrubba F, Massimino D, Schwartz RA. Dermatoscopy: alternative uses in daily clinical practice. J Am Acad Dermatol 2011; 64:1135.</a></li><li><a class="nounderline abstract_t">Errichetti E, Stinco G. Dermatoscopy of Granulomatous Disorders. Dermatol Clin 2018; 36:369.</a></li><li><a class="nounderline abstract_t">Motswaledi MH, Doman C. Lupus vulgaris with squamous cell carcinoma. J Cutan Pathol 2007; 34:939.</a></li><li><a class="nounderline abstract_t">Zawirska A, Adamski Z, Stawicka E, Schwartz RA. Cutaneous squamous cell carcinoma developing in lupus vulgaris exfoliativus persistent for 40 years. Int J Dermatol 2009; 48:125.</a></li><li><a class="nounderline abstract_t">Kanitakis J, Audeffray D, Claudy A. Squamous cell carcinoma of the skin complicating lupus vulgaris. J Eur Acad Dermatol Venereol 2006; 20:114.</a></li><li><a class="nounderline abstract_t">Kate MS, Dhar R, Borkar DB, Ganbavale DR. Longstanding lupus vulgaris with basal cell carcinoma. Indian J Pathol Microbiol 2009; 52:588.</a></li><li><a class="nounderline abstract_t">Vora NS, Dave JN, Mukhopadhyay A, et al. Basal cell carcinoma in a long standing case of lupus vulgaris. Indian J Dermatol Venereol Leprol 1995; 61:109.</a></li><li><a class="nounderline abstract_t">Almagro M, Del Pozo J, Rodríguez-Lozano J, et al. Metastatic tuberculous abscesses in an immunocompetent patient. Clin Exp Dermatol 2005; 30:247.</a></li><li><a class="nounderline abstract_t">Yeh LJ, Shively NR, Isacke RN, et al. Miliary tuberculosis characterised by lipomembranous fat necrosis. Lancet Infect Dis 2015; 15:1497.</a></li><li><a class="nounderline abstract_t">Koh HY, Tay LK, Pang SM, Ong BH. Changing the way we diagnose tuberculids with interferon gamma release assays. Australas J Dermatol 2012; 53:73.</a></li><li><a class="nounderline abstract_t">Victor T, Jordaan HF, Van Niekerk DJ, et al. Papulonecrotic tuberculid. Identification of Mycobacterium tuberculosis DNA by polymerase chain reaction. Am J Dermatopathol 1992; 14:491.</a></li><li><a class="nounderline abstract_t">Mascaró JM Jr, Baselga E. Erythema induratum of bazin. Dermatol Clin 2008; 26:439.</a></li><li><a class="nounderline abstract_t">Gupta V. Papulonecrotic tuberculid with scrofuloderma: an uncommon association. J Clin Diagn Res 2015; 9:WD03.</a></li><li><a class="nounderline abstract_t">Milligan A, Chen K, Graham-Brown RA. Two tuberculides in one patient--a case report of papulonecrotic tuberculide and erythema induratum occurring together. Clin Exp Dermatol 1990; 15:21.</a></li><li><a class="nounderline abstract_t">Chuang YH, Kuo TT, Wang CM, et al. Simultaneous occurrence of papulonecrotic tuberculide and erythema induratum and the identification of Mycobacterium tuberculosis DNA by polymerase chain reaction. Br J Dermatol 1997; 137:276.</a></li><li><a class="nounderline abstract_t">Thappa DM, Karthikeyan K, Jayanthi S. Tuberculid in a child: transformation from papulonecrotic to lichen scrofulosorum. Pediatr Dermatol 2003; 20:91.</a></li><li><a class="nounderline abstract_t">Morrison JG, Fourie ED. The papulonecrotic tuberculide. From Arthus reaction to lupus vulgaris. Br J Dermatol 1974; 91:263.</a></li><li><a class="nounderline abstract_t">Senol M, Ozcan A, Aydin A, et al. Disseminated lupus vulgaris and papulonecrotic tuberculid: case report. Pediatr Dermatol 2000; 17:133.</a></li><li><a class="nounderline abstract_t">Almeida BM, Challacombe SJ, Hay RJ, et al. Papulonecrotic tuberculide complicating scrofuloderma in a health-care worker. Br J Dermatol 1998; 139:550.</a></li><li><a class="nounderline abstract_t">Arora S, Arora G, Kakkar S. Cutaneous tuberculosis: A clinico-morphological study. MJAFI 2006; 62:334.</a></li><li><a class="nounderline abstract_t">Wong S, Rizvi H, Cerio R, O'Toole EA. An unusual case of vulval papulonecrotic tuberculid. Clin Exp Dermatol 2011; 36:277.</a></li><li><a class="nounderline abstract_t">Jordaan HF, Schneider JW, Schaaf HS, et al. Papulonecrotic tuberculid in children. A report of eight patients. Am J Dermatopathol 1996; 18:172.</a></li><li><a class="nounderline abstract_t">Freiman A, Ting P, Miller M, Greenaway C. Papulonecrotic tuberculid: a rare form of cutaneous tuberculosis. Cutis 2005; 75:341.</a></li><li><a class="nounderline abstract_t">Jordaan HF, Van Niekerk DJ, Louw M. Papulonecrotic tuberculid. A clinical, histopathological, and immunohistochemical study of 15 patients. Am J Dermatopathol 1994; 16:474.</a></li><li><a class="nounderline abstract_t">Singal A, Bhattacharya SN. Lichen scrofulosorum: a prospective study of 39 patients. Int J Dermatol 2005; 44:489.</a></li><li><a class="nounderline abstract_t">Singal A, Kaur I, Pandhi D, et al. Clinico-epidemiological profile of lichen scrofulosorum: a 22-year, single-center, retrospective study. Int J Dermatol 2021; 60:1278.</a></li><li><a class="nounderline abstract_t">Park YM, Kang H, Cho SH, Cho BK. Lichen scrofulosorum-like eruption localized to multipuncture BCG vaccination site. J Am Acad Dermatol 1999; 41:262.</a></li><li><a class="nounderline abstract_t">Tobita R, Sumikawa Y, Imaoka K, et al. Lichen scrofulosorum caused by pulmonary Mycobacterium avium complex (MAC) infection. Eur J Dermatol 2011; 21:619.</a></li><li><a class="nounderline abstract_t">Komatsu H, Terunuma A, Tabata N, Tagami H. Mycobacterium avium infection of the skin associated with lichen scrofulosorum: report of three cases. Br J Dermatol 1999; 141:554.</a></li><li><a class="nounderline abstract_t">Jacobsen G, Samolitis NJ, Harris RM. Lichenoid eruption in a patient with AIDS--lichen scrofulosorum (LS) tuberculid with underlying MAC infection. Arch Dermatol 2006; 142:385.</a></li><li><a class="nounderline abstract_t">Sehgal VN, Srivastava G, Khurana VK, et al. An appraisal of epidemiologic, clinical, bacteriologic, histopathologic, and immunologic parameters in cutaneous tuberculosis. Int J Dermatol 1987; 26:521.</a></li><li><a class="nounderline abstract_t">Gilchrist H, Patterson JW. Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management. Dermatol Ther 2010; 23:320.</a></li><li class="breakAll">Lake EP, Worobec SM, Aronson IK. Panniculitis. In: Fitzpatrick's Dermatology, 9th ed, Kang S, Amagai M, Bruckner AL, et al (Eds), McGraw-Hill Education, 2019. p.1259.</li><li><a class="nounderline abstract_t">Lam YY, Chiu WK, Luk CK, Fung GP. A case of erythema induratum with pulmonary tuberculosis. J Paed Respirol Crit Care 2015; 11:8.</a></li><li><a class="nounderline abstract_t">Vera-Kellet C, Peters L, Elwood K, Dutz JP. Usefulness of Interferon-γ release assays in the diagnosis of erythema induratum. Arch Dermatol 2011; 147:949.</a></li><li><a class="nounderline abstract_t">Sim JH, Whang KU. Application of the QuantiFERON®-TB Gold test in erythema induratum. J Dermatolog Treat 2014; 25:260.</a></li><li><a class="nounderline abstract_t">Suárez Castañón C, Pérez Méndez C, Alvarez Cuesta CC, et al. [Erythema induratum of Bazin associated to Mycobacterium tuberculosis infection]. Arch Argent Pediatr 2012; 110:e43.</a></li><li><a class="nounderline abstract_t">Hallensleben ND, de Vries HJ, Lettinga KD, Scherpbier HJ. Tuberculids: cutaneous indicator diseases of Mycobacterium tuberculosis infection in young patients. J Eur Acad Dermatol Venereol 2016; 30:1590.</a></li><li><a class="nounderline abstract_t">Friedman PC, Husain S, Grossman ME. Nodular tuberculid in a patient with HIV. J Am Acad Dermatol 2005; 53:S154.</a></li><li><a class="nounderline abstract_t">Jordaan HF, Schneider JW, Abdulla EA. Nodular tuberculid: a report of four patients. Pediatr Dermatol 2000; 17:183.</a></li><li><a class="nounderline abstract_t">Sethuraman G, Ramesh V, Ramam M, Sharma VK. Skin tuberculosis in children: learning from India. Dermatol Clin 2008; 26:285.</a></li><li><a class="nounderline abstract_t">Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Drugs 2003; 63:535.</a></li><li class="breakAll">Tappeiner G. Tuberculosis and infections with atypical mycobacteria. In: Fitzparick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw Hill Medical, 2008. p.1768.</li><li><a class="nounderline abstract_t">Rao M, Kadam M, Rao S. Formulation and evaluation of topical formulation for cutaneous tuberculosis. Journal of Drug Delivery and Therapeutics 2018; 8:102.</a></li><li><a class="nounderline abstract_t">Rosa J, Machado TC, da Silva AK, et al. Isoniazid-Resveratrol Cocrystal: A Novel Alternative for Topical Treatment of Cutaneous Tuberculosis. Cryst Growth Des 2019; 19:5029.</a></li><li><a class="nounderline abstract_t">Dostrowsky A, et al. Dermatologic complications of BCG vaccination. Br J Dermatol 1963; 75:181.</a></li><li><a class="nounderline abstract_t">Baek SO, Ko HS, Han HH. BCG vaccination-induced suppurative lymphadenitis: four signs to pay attention to. Int Wound J 2017; 14:1385.</a></li></ol></div><div id="topicVersionRevision">Topic 15866 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/tb/publications/global_report/en/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization. Global tuberculosis report, 2019. https://www.who.int/tb/publications/global_report/en/ (Accessed on March 23, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Laennec RT. Traité de l'Auscultation Médiate Et des Maladies des Poumons Et du Coeur, Asselin and Cie, 1826. p.649.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8521366" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20244430" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The history of lupus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26616847" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cutaneous tuberculosis overview and current treatment regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Various presentations of cutaneous tuberculosis at a tertiary care centre: a one year prospective study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cutaneous tuberculosis in HIV-infected individuals: lessons learnt from a case series</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28670967" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence and factors associated with alcohol drinking among HIV and tuberculosis co-infected patients in Dar es Salaam, Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29452616" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31178102" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cutaneous tuberculosis: A great imitator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9336935" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12069638" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cutaneous tuberculosis: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25387498" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Update on cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23173930" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cutaneous tuberculosis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18564245" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Management of cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35583803" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinicoepidemiological characteristics of cutaneous tuberculosis in 1458 Indian patients: a retrospective analytical study from a tertiary care center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17350496" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cutaneous tuberculosis: A clinicopathological study of 50 cases from a tertiary care referral hospital</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21063513" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A clinicoepidemiological study of 50 cases of cutaneous tuberculosis in a tertiary care teaching hospital in pokhara, Nepal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A clinicopathological study of cutaneous tuberculosis at Pune district, Maharashtra</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22121276" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A clinical and histopathological profile of patients with cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22121276" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A clinical and histopathological profile of patients with cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22121276" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A clinical and histopathological profile of patients with cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22121276" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A clinical and histopathological profile of patients with cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22121276" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A clinical and histopathological profile of patients with cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22121276" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A clinical and histopathological profile of patients with cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27957506" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Use of Nucleic Acid Amplification Tests in Tuberculosis Patients in California, 2010-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30531542" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nested Polymerase Chain Reaction and Cutaneous Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30111996" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cutaneous Tuberculosis: Clinicopathologic Arrays and Diagnostic Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29341430" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Tuberculosis vaccines: Opportunities and challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29341430" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tuberculosis vaccines: Opportunities and challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Review on convectional and advanced diagnostic techniques of human tuberculosis (TB) in Ethiopia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30429139" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cutaneous Mycobacterial Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20300359" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Techniques of skin biopsy and practical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Testing for tuberculosis: the roles of tuberculin skin tests and interferon gamma release assays</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Revisiting Mantoux test in the era of immunization and Multi-drug resistant tuberculosis (MDR-TB)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25054739" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cutaneous tuberculosis: diagnosis, histopathology and treatment - part II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21513844" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Diagnostic value of an enzyme-linked immunospot assay for interferon-γin cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cutaneous Tuberculosis: a Review of the Current Literature</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32248381" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comparison of conventional and molecular methods in diagnosis of extrapulmonary (cutaneous) tuberculosis in a tertiary care hospital in Delhi</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20725570" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cutaneous tuberculosis: a practical case report and review for the dermatologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10192161" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Detection of Mycobacterium tuberculosis DNA using polymerase chain reaction in cutaneous tuberculosis and tuberculids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15638300" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The accuracy and reliability of nucleic acid amplification tests in the diagnosis of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22910569" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Skin biopsy: a pillar in the identification of cutaneous Mycobacterium tuberculosis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11242621" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical utility of polymerase chain reaction in the detection of Mycobacterium tuberculosis in different types of cutaneous tuberculosis and tuberculids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694493" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Polymerase chain reaction based detection of Mycobacterium tuberculosis in tissues showing granulomatous inflammation without demonstrable acid-fast bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10651697" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Development of a polymerase chain reaction dot-blotting system for detecting cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17642890" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Utility of polymerase chain reaction as a diagnostic tool in cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23254731" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : mRNA and DNA PCR tests in cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689209" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : How soon does cutaneous tuberculosis respond to treatment? Implications for a therapeutic test of diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17675732" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : What is the appropriate duration of a therapeutic trial in cutaneous tuberculosis? Further observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Tattoo induced cutaneous tuberculosis: a rare occurrence</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20711276" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Three cases of primary inoculation tuberculosis as a result of illegal acupuncture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25860477" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Primary inoculation tuberculosis: a report of a rare entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7805294" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21144685" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : [Cutaneous infections related to permanent tattooing].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26143431" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Tuberculosis and Leprosy: Classical Granulomatous Diseases in the Twenty-First Century.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23157786" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cutaneous tuberculosis simulating lymphocutaneous sporotrichosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23157786" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cutaneous tuberculosis simulating lymphocutaneous sporotrichosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23157786" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cutaneous tuberculosis simulating lymphocutaneous sporotrichosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23157786" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cutaneous tuberculosis simulating lymphocutaneous sporotrichosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25678972" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Primary cutaneous tuberculosis in a 27-year-old medical intern from needle-stick injury: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25678972" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Primary cutaneous tuberculosis in a 27-year-old medical intern from needle-stick injury: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11204531" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tuberculosis verrucosa cutis (TBVC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11204531" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Tuberculosis verrucosa cutis (TBVC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12072004" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Tuberculosis verrucosa cutis on the sole of the foot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A clinicoepidemiological study of cutaneous tuberculosis in a tertiary care teaching hospital in Andhra Pradesh, India</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25673949" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Interferon-gamma release assay in a patient with tuberculosis verrucosa cutis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cutaneous tuberculosis- a clinico-histopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19002356" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Bilateral scrofuloderma of the axilla masquerading as hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12220277" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Scrofuloderma after BCG vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24448136" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Scrofuloderma associated with tuberculosis verrucosa cutis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16681617" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Symmetrical scrofuloderma with tuberculosis verrucosa cutis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31660379" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Tuberculosis Cutis Orificialis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6806336" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15857468" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Perianal ulceration: a case of tuberculosis cutis orificialis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20523845" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A case of tuberculosis cutis orificialis with perianal involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687430" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Persistent perianal ulcers. Tuberculosis cutis orificialis (TCO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10383062" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cutaneous tuberculosis: a twenty-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A profile of cutaneous tuberculosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A ten year prospective clinicopathological study of cutaneous tuberculosis at a tertiary care hospital in coastal Karnataka</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Clinico-epidemiological study of cutaneous tuberculosis in a tertiary care hospital of Rajasthan</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12653914" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Incidence of cutaneous tuberculosis in patients with organ tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Clinical presentations of cutaneous tuberculosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1564144" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Lupus vulgaris. Clinical, histopathologic, and bacteriologic study of 10 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13471498" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The safety record of BCG vaccination and untoward reactions observed after vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14400192" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Uncommon skin reactions after BCG vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7657867" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cutaneous tuberculosis: a clinical, histopathologic, and bacteriologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26794085" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Twenty-nine cases of lupus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22056255" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : [Lupus vulgaris caused by Mycobacterium bovis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Unusual clinical presentation of cutaneous tuberculosis caused by Mycobacterium bovis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Disseminated lupus vulgaris: A case report</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21772608" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Childhood multicentric lupus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21738972" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cutaneous tuberculosis and squamous-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292346" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Dermatoscopy: alternative uses in daily clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30201146" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Dermatoscopy of Granulomatous Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18001418" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Lupus vulgaris with squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19200184" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Cutaneous squamous cell carcinoma developing in lupus vulgaris exfoliativus persistent for 40 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16405629" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Squamous cell carcinoma of the skin complicating lupus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19805990" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Longstanding lupus vulgaris with basal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20952907" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Basal cell carcinoma in a long standing case of lupus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15807681" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Metastatic tuberculous abscesses in an immunocompetent patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26607131" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Miliary tuberculosis characterised by lipomembranous fat necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22309338" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Changing the way we diagnose tuberculids with interferon gamma release assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1471746" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Papulonecrotic tuberculid. Identification of Mycobacterium tuberculosis DNA by polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18793975" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Erythema induratum of bazin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25859507" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Papulonecrotic tuberculid with scrofuloderma: an uncommon association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2311274" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Two tuberculides in one patient--a case report of papulonecrotic tuberculide and erythema induratum occurring together.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292081" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Simultaneous occurrence of papulonecrotic tuberculide and erythema induratum and the identification of Mycobacterium tuberculosis DNA by polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12558860" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Tuberculid in a child: transformation from papulonecrotic to lichen scrofulosorum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4279670" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The papulonecrotic tuberculide. From Arthus reaction to lupus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792804" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Disseminated lupus vulgaris and papulonecrotic tuberculid: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9767317" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Papulonecrotic tuberculide complicating scrofuloderma in a health-care worker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Cutaneous tuberculosis: A clinico-morphological study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21418269" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : An unusual case of vulval papulonecrotic tuberculid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8739993" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Papulonecrotic tuberculid in children. A report of eight patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16047872" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Papulonecrotic tuberculid: a rare form of cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7802163" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Papulonecrotic tuberculid. A clinical, histopathological, and immunohistochemical study of 15 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15941438" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Lichen scrofulosorum: a prospective study of 39 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34181284" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Clinico-epidemiological profile of lichen scrofulosorum: a 22-year, single-center, retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10426899" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Lichen scrofulosorum-like eruption localized to multipuncture BCG vaccination site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21616750" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Lichen scrofulosorum caused by pulmonary Mycobacterium avium complex (MAC) infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583068" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Mycobacterium avium infection of the skin associated with lichen scrofulosorum: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549721" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Lichenoid eruption in a patient with AIDS--lichen scrofulosorum (LS) tuberculid with underlying MAC infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3119506" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : An appraisal of epidemiologic, clinical, bacteriologic, histopathologic, and immunologic parameters in cutaneous tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20666819" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20666819" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : A case of erythema induratum with pulmonary tuberculosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844454" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Usefulness of Interferon-γrelease assays in the diagnosis of erythema induratum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22920648" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Application of the QuantiFERON®-TB Gold test in erythema induratum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22760758" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : [Erythema induratum of Bazin associated to Mycobacterium tuberculosis infection].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27225025" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Tuberculids: cutaneous indicator diseases of Mycobacterium tuberculosis infection in young patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16021168" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Nodular tuberculid in a patient with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10886748" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Nodular tuberculid: a report of four patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18346559" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Skin tuberculosis in children: learning from India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12656652" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12656652" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Formulation and evaluation of topical formulation for cutaneous tuberculosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Isoniazid-Resveratrol Cocrystal: A Novel Alternative for Topical Treatment of Cutaneous Tuberculosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Dermatologic complications of BCG vaccination</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28425207" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : BCG vaccination-induced suppurative lymphadenitis: four signs to pay attention to.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
